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Strong evidence supports the role of genetic endowment conferring either 
vulnerability or protection to mood disorders.  However, environmental factors 
are also known to play a critical modulating role in such vulnerability. Recent 
reports revealed decreased levels of Fibroblast Growth Factor-2 (FGF-2) gene 
expression in several post-mortem brain regions of subjects with a history of 
major depression.  One of the regions showing profound alterations was the 
hippocampus of these severely depressed subjects.  These reports implicated 
FGF-2 in depression, however they did do not address whether the observed 
dysregulation in FGF-2 expression represents a predisposing factor to the illness 
or a consequence of the disease process.  Given that altered anxiety is observed 
in mood disorders such as depression we examined the potential contribution of 
FGF-2 in two genetically distinct groups of rats selectively bred to differ 
dramatically in their response to novelty and to anxiety-provoking conditions 
(HRs= Low Anxiety/High Response to Novelty vs. LRs= High Anxiety/Low 
Response to Novelty). We demonstrate that the Low-Anxious HRs have 
significantly elevated levels of hippocampal FGF-2 mRNA relative to the High-
Anxious LR’s, and that there exists a highly significant inverse correlation 
between FGF-2 levels and anxiety behavior. Interestingly, FGF-2 expression is 
modulatable by environmental factors that alter anxiety and enhance 
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neurogenesis-- thus environmental complexity (EC) reduces anxiety behavior 
induces FGF-2 expression and promotes neurogenesis in the hippocampus, 
particularly in the High Anxious LR’s.  Moreover, a 3-week treatment regimen of 
administered FGF-2 is highly effective at blunting anxiety behavior, specifically in 
the High Anxious LR’s.  This anxiolytic effect is accompanied by an increase in 
the survival of hippocampal adult stem cells, both neurons and astrocytes, again 
specifically in the LR’s.  Furthermore, we show that the impact of EC on 
hippocampal cell genesis is dependent on the FGF system as FGF blockade 
disrupted the effects of EC on increasing cell proliferation and new cell survival. 
This suggests that hippocampal cell genesis might contribute to modulating the 
anxiolytic effects of FGF-2 and EC. Taken together, these findings implicate 
hippocampal FGF-2 as a novel modulator of anxiety behavior and underscore its 
potential as a new target for the treatment of mood and anxiety disorders.
 
 1 




It is increasingly evident that behavior, including emotional responsiveness, is 
controlled by the interplay between genetic predisposition and the impact of the 
environment on the individual.  While genetic endowment may confer either 
vulnerability or protection towards a high level of emotional reactivity and stress 
responsiveness, environmental factors are also thought to play a critical 
modulating role.  In particular, early life stress is known to alter emotionality later 
in life.  Moreover, acute psychosocial stress (so-called life events) is often the 
trigger for episodes of severe mood disorders.  However, less is known about the 
protective consequences of the environment and how they might interact with 
genetic vulnerability to anxiety, a behavior often seen altered in mood disorders.  
 
Emotionality refers to the unique constellation and magnitude of the endocrine, 
neural and behavioral responses of an organism in response to environmental 
stimuli that have valence, be it negative or positive.  The hippocampus along with 
its well-known function in learning and memory (Squire, 1992, Jarrard, 1993) is 
one of the key brain structures that modulate these stress responses via its 
negative feedback regulation (Jacobson and Sapolsky, 1991). Exposure to 
sustained stress increases anxiety-like behavior and can lead to various 
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structural and synaptic plasticity changes in the hippocampus (Kim and Yoon, 
1998) (Sapolsky, 2003), including dendritic remodeling and disruption of 
proliferation and survival of adult neurogenesis (McEwen, 2001). Such changes 
are in part thought to underlie the neural mechanisms associated with altered 
cognitive and emotional behaviors seen in mood disorders (Duman, 2002, 
McEwen, 2005). 
 
As mentioned above, genetic as well as environmental factors are thought to 
modulate emotionality.  Genetic influences on emotionality have been evident in 
the selectively bred HR (High Responder) and LR (Low Responder) animals.  
HR-LR animals show characteristic differences in emotional responsiveness to 
novelty where HR animals show higher locomotor response to a novel 
environment as opposed to LRs, which display limited response to novelty.  
These differences in response to novelty have previously been shown to predict 
propensity to drug-taking behavior, where HRs learn to self-administer drug of 
abuse more readily than LRs, including cocaine and amphetamine (Piazza et al., 
1990).  HR-LR animals also show predictable differences in anxiety-like behavior, 
where HRs display low anxiety relative to the highly anxious LRs (Kabbaj et al., 
2000).  Recently, the genetic contribution brought by these behavioral 
phenotypes was demonstrated as selective breeding showed these behavioral 
phenotypes being highly heritable (Stead et al., 2006).  Thus selective breeding 
of HRs and LRs has been shown to confer differences in vulnerability to anxiety-
like behavior.  
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Findings by our laboratory support the role of the hippocampus as a key structure 
modulating differences in propensity to anxiety-like behavior between HR-LR. 
Specifically, HR animals show lower levels of glucocorticoid receptor GR 
expression in the hippocampus relative to LRs.  These differences in 
hippocampal GR are thought to modulate in part such differences in anxiety as 
direct microinjections with a GR antagonist into the hippocampus of LRs reduces 
their anxiety to that of an HR (Kabbaj et al., 2000).  
 
Conversely, HR-LR differences in emotionality are also subject to differential 
propensity to stress impact as social isolation confers an anxiogenic effect in 
HRs without affecting LRs (Kabbaj et al., 2000).  Similarly, restraint stress causes 
HR animals to behave like LR animals.  This suggests that stressful experiences 
may also differentially affect the typical HR-LR anxiety responses.  Moreover, 
differences in HR-LR behavioral responses to environmental stimulation also 
extend to differences in neural responses as observed by immediate early gene 
expression.   
 
Changes in immediate early gene expression in response to stress or 
environmental stimulation are thought to precede short and long-term changes 
resulting from environmental stimulation (Kabbaj and Akil, 2001). Furthermore, 
growth factor gene expression changes resulting from environmental stimulation 
are thought to initiate changes in structural plasticity (Rampon et al., 2000) 
(McClung and Nestler, 2008).   As mentioned above the hippocampus is one the 
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key brain structures showing high responsiveness to stress and environmental 
stimulation.  Such responsiveness has been shown to result in structural 
plasticity changes including changes in dendritic arborization, synaptogenesis 
and neurogenesis.   
 
Growth factors are thought to mediate in part most of these structural plasticity 
changes occurring in the brain (Filus and Rybakowski, 2005, McClung and 
Nestler, 2008).  These include changes in neurogenesis associated with VEGF 
expression as well as changes in dendritic remodeling in response to FGF-2 
(Cao et al., 2004, Rai et al., 2007).  Moreover, the role of growth factors in 
structural plasticity in the hippocampus has been extended by their genetic 
contribution, observed in animals showing overexpression or deletion of growth 
factor genes (Govindarajan et al., 2006) (Raballo et al., 2000, Korada et al., 
2002).  
 
As mentioned above, HR and LR animals show heritable differences in 
emotionality and differences in response to environmental stimulation.  Given 
that growth factors have been singled out as key players modulating structural 
plasticity resulting from genetic contribution and experience, it is reasonable to 
suspect that differences in HR-LR anxiety-like behavior and response to 




Previous work has mostly focused on growth factors such as BDNF and VEGF in 
modulating structural plasticity changes resulting from antidepressant treatment.  
Specifically, changes in anxiety and depression-like behavior have been 
attributed to changes in neurogenesis brought by VEGF and BDNF  (Shirayama 
et al., 2002) (Warner-Schmidt and Duman, 2007) (Schmidt and Duman, 2007).  
However, work in our group has led to a novel set of target growth factors that 
may also participate in modulating differences in anxiety seen in HR and LR.  
 
Previous microarray studies performed by a consortium of researchers that 
includes our laboratory (the Pritzker Consortium) have revealed decreased levels 
of Fibroblast Growth Factor-2 (FGF-2) gene expression in several post-mortem 
brain regions of subjects with a history of major depression (Evans et al., 2004).  
These differences in FGF-2 transcripts seemed to partially reverse with 
antidepressant treatment.  Furthermore, recent, unpublished observations have 
shown that the hippocampus of these severely depressed subjects shows the 
most profound alterations.  
 
While evidence implicating FGF-2 in emotional behavior is limited, studies 
suggest that experiences that affect emotional behavior influence FGF-2 gene 
expression.  For example; rats that were raised by mothers who demonstrated 
better care for their pups, showed higher protein levels of FGF-2 and enhanced 
survival of adult-born neurons (Bredy et al., 2003).  In turn, rats that received 
increased maternal care show reduced endocrine stress responses and better 
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adaptive behaviors towards environmental challenges (Francis and Meaney, 
1999, Menard et al., 2004).  Interestingly, the deficits in hippocampal 
development resulting from decreased maternal care have been shown to be 
rescued by environmental complexity (EC) (Bredy et al., 2004).  EC has also 
been shown to reverse the behavioral, neurogenic and endocrine deficits 
resulting from prenatal restraint stress (Morley-Fletcher et al., 2003, Laviola et 
al., 2004).  While these reports generally support the role of EC in modulating 
emotional behavior, it remains to be determined whether EC increases FGF-2 
expression in the adult hippocampus. Furthermore, prenatal stress has been 
shown to reduce both neurogenesis (Coe et al., 2003), and levels of FGF-2 in the 
hippocampus of adult rats (Molteni et al., 2001), EC reverses the effects of stress 
on neurogenesis (Morley-Fletcher et al., 2003, Laviola et al., 2004).  Given that 
FGF-2 enhances neurogenesis on mature adults and during early development, 
one might predict that the reversal effects of EC may in part be due to a rescue 
of basal levels FGF-2. 
 
Given that anxiety is one of the strong hallmarks of vulnerability to depression in 
humans, it is reasonable to consider that experiences known to reduce anxiety 
and enhance neurogenesis may help elucidate the role of FGF-2 in emotionality.  
Moreover as HR and LR animals show basal differences in emotionality (e.g 
anxiety-like behavior), which are subject to experiential influence, our studies will 
examine the potential role of FGF-2 on emotionality where the genetic and 
experiential contributions are taken into account. 
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Fibroblast Growth Factors 
 
FGF-2 is a member of the FGF gene family composed of 24 proteins that have 
multiple functions including development of the nervous system and 
angiogenesis (Eckenstein et al., 1991).  FGF-2 and other FGF ligands are 
classified as family members based on a central domain conserved region of 
about 120 amino acids which bind heparin (Faham et al., 1996). The typical 
genomic structure of this family is made up of three coding exons ranging from 
5kb to 100kb, where exon one contains the start codon.  The family can also be 
subdivided into three groups.  One subgroup; FGF 1, 2, 9, 16 and 20 lack an NH-
2 terminal signal sequence but they are still transported to the extracellular 
environment, while FGF 11- FGF 14 also lack this signal and remain intracellular.  
The remaining FGF subgroup uses the endoplasmic reticulum-golgi secretory 
pathway to be transported extracellularly.  
  
 The complexity produced by the diversity of family member ligands includes 
different isoforms resulting in some members such as FGF-2 and FGF-3, which 
have additional 5’ transcribed sequences from upstream AUG starting codons 
(Arnaud et al., 1999). These isofoms are said to confer different functions to the 
protein and affect affinity for the FGF receptors.  For example amino terminal 
extensions of bFGF or FGF-2 have been hypothesized to promote nuclear 
targeting of the protein, thereby regulating different functional responses within 
the cells (Bikfalvi et al., 1998). On the other hand, several factors contain a single 
start codon (Gaughran et al.), but exon one is subdivided into two to four different 
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subexons by alternative splicing.  Others use alternative 5’exons, which will 
confer them with alternative amino terminals.  These transcriptional variations 
may also have some implications for receptor affinity and tissue specificity, which 
ultimately may translate to different functional activity. 
 
Fibroblast Growth Factors; Structural Characteristics of FGF-2  
 
FGF-2 has been crystallized and characterized structurally by (Zhu et al., 1991).  
Its structure is important to discuss since its interaction with FGF receptors is 
made up of a terciary complex that also includes interactions with heparan 
sulfate, which can also affect cell activity response.  Several isofoms of FGF 2 
ranging from 18 kDa to 24 kDa have been identified.  The crystal structure of the 
18kDA isoform was determined in the presence and absence of heparan sulfate 
by (Faham et al., 1996).  FGF 2 is composed of 12 antiparallel β-sheets within 
the conserved core domain organized as a pyramidal structure of three groups of 
4 β-sheets. Beta strands 10 and 11 contain several basic residues that form the 
heparin-binding site, which provide protection against denaturing agents 
(Schlessinger et al., 2000).  Heparan sulfate which is found throughout all the 
mammalian tissues, contrary to heparin, will have a role in modulating FGF2 
function and distribution by binding FGF-2 as soon as it is secreted from cells. 
This in turn will affect ligand–receptor binding interaction.  
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Fibroblast Growth Factor-2; Receptors 
 
In the adult, FGF-2 shows prominent expression in the cytoplasm as well as in 
the nucleus of astrocytes throughout the brain, whereas neuronal expression is 
almost exclusive to the hippocampus (Woodward et al., 1992).  Several isoforms 
of FGF 2 ranging from 18 kD to 34 kD have been identified (Nugent and Iozzo, 
2000).  FGF-2 exerts its function by interacting with four receptor types with 
varying affinity depending on ligand and receptor isoforms (Ornitz, 2000, Reuss 
and von Bohlen und Halbach, 2003).  These receptors are trans-membrane 
glycoproteins containing three Ig-like loops (I-II-III) in the extracellular domain 
and a split tyrosine kinase domain.  Three of the FGF receptors, FGFR1, FGFR2 
and FGFR3, are expressed in the brain (Eckenstein, 1994), while FGFR1 is most 
abundantly expressed in the hippocampus (Belluardo et al., 1997). There are two 
binding sights from where bFGF can interact with the FGF receptors.  This gives 
a chance for one FGF-2 molecule to bind to two different receptors at the same 
time or activate a single receptor within two different locations, (Kan et al., 1993). 
This same group has also shown that FGF receptor 1 contains heparan sulfate 
binding sites, and have suggested that this interaction functions to enhance 
FGF2 affinity to receptors (Kan et al., 1999).  Affinity for receptors by FGF-2 and 
other family members is modulated by different factors such as receptor isoforms 
and the types of heparan sulfate proteoglycans on the cell surface, (Guimond 
and Turnbull, 1999), (Lin et al., 1999), (Ornitz et al., 1996), (Spivak-Kroizman et 
al., 1994).  The Ig-III loop is the site of specificity for the receptor, (Johnson et al., 
1991) and it is where isoforms are formed, hatl enhance or decrease the affinity 
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of the receptors 1,2 and 3 for any given FGF.  These isoforms (IIIb or IIIc) are 
formed through alternative splicing of two exons that code for the carboxyl 
terminal half of the loop III.  FGF binding affinity studies have been done in cell 
culture using Baf 3 cells (Ornitz et al., 1996).  The results suggest that FGF-2 has 
a higher affinity for FGF receptors 1IIIc and 3 IIIc and FGF receptor 4 while 
showing very low affinity for isoforms of receptor 2 IIIb and 3 IIIb. 
 
Fibroblast Growth Factor-2; Anatomy 
 
The expression of FGF-2 in the adult brain has been observed by 
immunohistochemistry showing FGF-2 most prominently expressed in astrocytes 
throughout the whole CNS including the hippocampus and the neocortex 
(Woodward et al 1992).  The only reported immunoreactivity of FGF-2 on 
neurons was in the hippocampal formation.   FGF 2 expression was found in the 
cytoplasm as well as in the nucleus of both astrocytes and neurons.  In the rat 
brain FGF-2 is widely expressed across regions with most prominent expression 
in astrocytes.  Anatomical mapping shows FGF-2 synthesizing cells showing high 
co-localization with FGF-2 protein expression (Gonzalez et al. 1995). Thus most 
astrocytes synthesize FGF-2 whereas FGFr1 is mostly neuronal.  Interestingly, 
FGF-2 mRNA shows low abundance in the dentate gyrus, whereas protein 
expression is very high in abundance.  FGF-2 expression in the hippocampus is 
much higher in the CA2 with lower levels of expression observed in the CA1 and 
CA3.  This suggests that FGF-2 action must be relatively localized within each 
hippocampal subregion as its synthesis in astrocytes must impact FGFr1 
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neuronal cells located in the hippocampus.  On the other hand it is also possible 
that FGF-2 synthesized within the hippocampus could be acting outside of this 
region.  This is particularly evident in regions such as the amygdala where FGF-2 
mRNA expression is almost absent, yet high protein expression is observed. 
Moreover, the amygdala shows high levels of FGFr1 expression suggesting that 
FGF-2 stemming from other regions should be acting in these receptors.  This is 
consistent with reports showing FGF-2 as a diffuseable protein.  Moreover, FGF 
receptors are mostly expressed within axonal fibers, thus most of FGF-2 activity 
within the receptors should stem from secreted FGF-2 as oligodendrocytes do 
not synthesize FGF-2. Finally although most of the FGF receptors are expressed 
in the white matter only FGFr1 is expressed in neuronal populations, with high 
levels of expression found in the hippocampus including the dentate gyrus and 
the CA3 subregions. 
 
Fibroblast Growth Factor-2; Cell signaling 
 
Signaling cascades by FGF receptor activation have been determined and 
hypothesized to involve mitogenic activation, but the target molecular pathways 
for specific functions have yet to be determined.  These signals depend on 
receptor isoforms as well as glycoprotein interaction within the cell surface, as 
previously mentioned.   Binding of FGF-2 will activate the receptor, which will 
cause dimerization and autophosphorylation by specific tyrosine residues within 
the receptor.  Then binding of phospholipase C to phosphotyrosine residues will 
mediate signal, through hydrolysis of phosphatidylinositol to inositol-3-phophate 
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and dyacilglycerol (DAG) leading to Ca+ release and subsequent activation of 
PKC.  Another signal transduction pathway involving FGF receptor activation is 
through binding of FGF substrate receptor 2 (FRS2) and/or SHC.  These will stay 
bound to tyrosine residues within the receptor and bind the Grb2-SOS complex 
activating RAS.  In turn Ras recruits RaF-1, which will then phosphorylate MEK, 
followed by phosphorylation of MAPK by MEK, resulting in activation and 
phosphorylation of transcription factors.  Both of these signaling cascades have 
been attributed to FGF-2 function. However many factors mentioned above may 
affect which cell signaling cascades regulate FGF-2 functional responses at 
different times. 
 
Fibroblast Growth Factor-2; Development 
 
Basic FGF or FGF-2 has been shown to play an important role during embryonic 
development of the neocortex and hippocampus of mice (Vaccarino et al., 1999, 
Raballo et al., 2000, Cheng et al., 2002) however its enhancing proliferative 
effects on neurons have not been extensively studied in the adult brain.   
Expression of FGF-2 and its receptors FGFr 1,2 and 3 during development is 
temporally regulated within the ventricular zone (VZ), which is the area from 
where inducing signals for neocortical progenitors occur reviewed by (Ford-
Perriss et al., 2001).  The progenitors cells within the VZ express high levels of 
bFGF whereas migrating cells once they leave the VZ do not.   FGF-2 is 
expressed early during neurogenesis, becoming almost absent by the end, when 
other growth factors such as FGF-7 and FGF-8 increase expression (reviewed by 
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(Dono, 2003).  Most studies on FGF-2’s role in development have focused on 
neocortical progenitor cell cultures whereas its mitogenic and survival effects 
have been documented by (Murphy et al., 1990), (Cavanagh et al., 1997).  
Moreover, (Palmer et al., 1995) (Palmer et al., 1999) showed the neurogenic 
effects of bFGF in vitro from stem cells of adult neocortex an area where only 
glial proliferate during adulthood.    
  
Furthermore studies done by (Korada et al., 2002) showed that FGF-2 knockout 
mice had a decrease of 40% in cortical glutamatergic pyramidal neurons and a 
reduction in the size of their cell bodies, with no effects observed in the 
hippocampus.  These effects were restricted to frontal and parietal cortex.  
Furthermore, FGF-2 injected at Embryonic day 15.5 to null mutants results in an 
18% and 87% increase in the volume and in total number of neurons, 
respectively in the adult cerebral cortex (Vaccarino et al., 1999). Finally studies 
have also demonstrated the role of bFGF in cholinergic sprouting and axonal 
remodeling after entorhinal cortex lesions, (Ramirez et al., 1999) (Fagan et al., 
1997). Taken together these reports exemplify the variety of responses and 
actions FGF-2 provides throughout the brain during development.  However, this 
does not address the variety of neurogenic responses FGF-2 could bring about in 
the postnatal brain. 
 
FGF-2 has mostly been recognized for its mitogenic and survival effects on adult 
stem cell cultures derived from numerous areas of the central nervous system 
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(Palmer et al., 1999). These include areas such as the striatum, neocortex, and 
subventricular zone, which have shown proliferative responses from exposure to 
bFGF, inducing neurons and glia.   However, these neurogenic effects have only 
been reported in vivo during certain developmental periods.  For example single 
peripheral injections of FGF-2 have been shown to enhance hippocampal 
neurogenesis in young rodents, however these effects were not observed in the 
adult (Wagner et al., 1999).  It is possible that repeated injections might be 
required for such effects to take place, since repeated exogenous administration 
of FGF-2 rescues age related decline of hippocampal neurogenesis in mice and 
rats (Jin et al., 2003) 
 
Neurogenesis; Modulation by Environmental Factors 
 
Neurogenesis refers to neuronal birth, differentiation, and short-term survival of 
new neurons.  Neurogenesis occurs well into adulthood in certain areas of the 
brain, including the subventricular zone and the dentate gyrus of the 
hippocampus. In the adult rat hippocampus, neurogenesis occurs in the 
subgranular zone located at the border of the granule cell layer and hilus. New 
neurons in the dentate gyrus migrate into the granule cell layer, extend axons 
into the mossy fiber pathway, make synaptic contacts with targets in CA3, and 
express neuronal markers (van Praag et al., 2002). 
 
It is estimated that in the rat hippocampus the number of granule neurons added 
to the granule cell layer of the dentate gyrus within 1 month is 6% of the total 
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granule cell population, representing 28% and 62% of the afferent and efferent 
neuronal populations respectively (Cameron and McKay, 2001). This represents 
a massive cell turnover, which makes this structure particularly sensitive to 
experience-dependent changes. However, it also renders the dentate gyrus 
particularly susceptible to environmental factors, which could alter hippocampal 
structure and function. Indeed, exposure to negative regulators of hippocampal 
neurogenesis such as stress result in reduced performance on hippocampus-
dependent learning tasks (Luine et al., 1994, Bodnoff et al., 1995, Endo et al., 
1996, Krugers et al., 1997, Shors et al., 2001), while positive regulators such as 
exercise and environmental complexity correlate with improved performance 
(Kempermann et al., 1997, Luine et al., 1998, van Praag et al., 1999a). 
 
It has been shown that when rodents are housed in an enriched environment 
there is an increased in the numbers of new neurons in the dentate gyrus 
(Kempermann et al., 1997, Nilsson et al., 1999). This increase in number of both 
neurons and glia has been attributed to an enhanced survival of new cells as 
opposed to proliferation (Nilsson et al., 1999). Moreover, an increase in 
hippocampal volume has been seen after exposure to a complex environment.  
This suggests that adult neurogenesis facilitates the increase in hippocampal 
volume and that such increase in neurogenesis may help individuals cope better 





Similarly an increase in neurogenesis is observed in response to hippocampus-
dependent learning whereas no increase is observed following learning tasks 
that do not require the hippocampus (Gould et al., 1999, Ambrogini et al., 2000). 
This has been suggested to result form increased survival of new cells as 
opposed to proliferation, as most untrained animals see a reduction in 
neurogenesis within two weeks (Cameron et al., 1993), whereas animals living in 
a complex environment or trained in hippocampus-dependent learning tasks 
show reduced pyknosis  and increased neurogenesis in the hippocampal 
subgranular zone (Young et al., 1999) (Gould et al., 2000). 
 
Similarly, exercise increased neurogenesis in mice (van Praag et al., 1999a, van 
Praag et al., 1999b, van Praag et al., 2002), while enhancing hippocampal LTP, 
suggests that the integration of these new cells may have an active participation 
in synaptic plasticity.  Indeed it has been show that new cells born in the dentate 
gyrus show similar functional properties to those seen in mature neurons (van 
Praag et al., 2002). Interestingly, running has been shown to have 
antidepressant-like effects in rodents and humans which could therefore be 
mediated in part by increased hippocampal neurogenesis (Hill et al., 1993, Ernst 
et al., 2006).  This leads me to speculate that environmental complexity could 
perhaps have similar antidepressant effects as a result of increased 
neurogenesis, whereas stress could lead to an increase in vulnerability to mood 




In the adult hippocampus stress inhibits neurogenesis, and impairs learning and 
anxiety (Kim and Diamond, 2002). In rats, odor of a natural predator suppresses 
proliferation in the dentate gyrus (Tanapat et al., 2001). Similarly, in the 
marmoset stress provoked by introduction of a resident intruder decreases 
neurogenesis in the dentate gyrus (Gould et al., 1998). 
 
Stress and depression are associated with morphological changes in many brain 
regions including the hippocampus (Drevets, 2000, Rajkowska, 2000). For 
example, decreased hippocampal volume has been shown in patients suffering 
from depression (Sheline et al., 1996, Sheline et al., 1999) and post-traumatic 
stress disorder (PTSD) (Bremner et al., 1995, Gurvits et al., 1996, Bremner et al., 
1997).  Recently, similar findings were shown in rats where hippocampal volume 
was negatively correlated with Hippocampal volume (Kalisch et al., 2006). This 
reduction in volume has been attributed to a decrease in neurogenesis (Gould et 
al., 1998). Furthermore, studies have indicated that reduced hippocampal volume 
may predispose to, as opposed to result from, affective disorder as seen in twin 
studies from combat patients suffering from PTSD (Gilbertson et al., 2002).  
Taken together these findings along with the reports above, suggest that both 
experience and genetic propensity interact to produce the vulnerability to mood 
disorders with associated structural plasticity in the hippocampus. 
 
In fact it has been shown that prenatal stress predisposes adults to depression in 
humans and rats (Dugovic et al., 1999, Watson et al., 1999). In support of the 
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role of neurogenesis in such vulnerability (Lemaire et al., 2000) demonstrated 
that prenatal stress induces a life-long reduction in neurogenesis in the dentate 
gyrus of rats. 
 
While stress and depression may reduce hippocampal neurogenesis, possibly 
contributing to reduced hippocampal volume, proliferation is increased after 
chronic administration of antidepressants including SSRIs, (Malberg et al., 2000).  
Antidepressants increase the rate of hippocampal neurogenesis over a period of 
two to three weeks of administration. This is consistent with the time in takes for 
antidepressants to show beneficial effects on mood disorders. This suggests that 
increased adult neurogenesis may be a possible mediator of antidepressant 
action in humans (reviewed by (Duman et al., 2001, Manji et al., 2001, Jacobs, 
2002). 
 
The effects of antidepressants on neurogenesis have been extensively studied in 
animal models. Increases were observed in the rat following administration of 
several classes of antidepressants, while non-antidepressant agents had no 
effect on neurogenesis (Malberg et al., 2000). Furthermore, combined 
antidepressant treatment with stress in tree shrews and rats reverse the effects 
of stress on decreasing proliferation in the adult dentate gyrus, (Czeh et al., 




As a result it has been suggested that stress-induced decrease in neurogenesis 
may be an important factor in eliciting depressive episodes (Duman et al., 2001, 
Jacobs, 2002, Kempermann and Kronenberg, 2003).  Reports supporting this 
hypothesis have shown that animal model of stress disrupt cell proliferation and 
cell survival, while antidepressants reverse such effects (Czeh et al., 2002, 
Malberg and Duman, 2003).  Furthermore, it has been shown that the behavioral 
effects of antidepressants are dependent on neurogenesis in the hippocampus 
(Santarelli et al., 2003).  Reports also show that depressed subjects have 
decreased hippocampal volume when compared to normal subjects, whereas 
treated depressed subjects do not show such deficits (Sheline et al., 1996, 
Sheline et al., 1999).  These differences in hippocampal volume could in part be 
due to differences in neurogenesis brought by increased amounts of stress.  
While the above reported data suggest that decreased neurogenesis may 
underlie the behavioral deficits of depression (van Praag et al., 2000), the neural 
mechanisms responsible for decreased neurogenesis are yet to be determined. 
 
It has been well documented in animal models that stress has detrimental effects 
on emotional behavior and decreases hippocampal neurogenesis (Gould et al., 
1997, Tanapat et al., 1998, Malberg and Duman, 2003, Mirescu et al., 2004).  
Moreover, the effects of such stressful experiences are reversed by 
antidepressant treatment (Malberg and Duman, 2003).  Since antidepressants 
represent an effective treatment strategy, their mechanisms of action have been 
used as a point of departure for understanding the etiology of mood disorders 
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(Jacobs, 2002).  Thus, increased adult neurogenesis has been suggested as one 
of the mechanisms by which antidepressants exert their beneficial effects on 
behavioral measures of anxiety and depression-like behavior (Santarelli et al., 
2003).  The convergence of evidence, with stress decreasing and 
antidepressants increasing neurogenesis has led to the hypothesis that mood 
disorders may be related to decreased levels of neurogenesis in the 
hippocampus.  However, much remains to be done to fully determine whether 
decreased neurogenesis underlies the emotional distress seen in depression.  
Moreover, it is important to examine the interplay between neurogenesis and 
individual differences in emotionality, and especially the impact of experience on 
these processes, without relying exclusively on a treatment based-hypothesis 
(Grossman et al., 2003).  Non-aversive experiences such as Environmental 
Complexity (EC) show similar effects to antidepressants, including reducing 
anxiety and increasing neurogenesis (Kempermann et al., 1997, Benaroya-
Milshtein et al., 2004).  Understanding the mechanisms of action of EC will 
provide an insight into the neural mechanisms whereby certain types of 





Environmental complexity refers to housing conditions facilitating sensory, 
exercise and social stimulation provided by the addition of more animal, toys and 
obstacles in the housing environment (van Praag et al., 2000).  Animals living 
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under such housing conditions have shown many structural and behavioral 
plasticity effects relative to animals living on standard housing conditions.  These 
effects seem to underlie the mechanisms of action of the potential beneficial 
effects of experience, given that EC has been shown to ameliorate the effects of 
animal models of neurological disorders such as Alzheimer’s (AD), Parkinson’s 
and Fragile X among others (Nithianantharajah and Hannan, 2006). 
 
As mentioned above, EC has been shown to have a variety of effects from 
behavioral to cellular and molecular (van Praag et al., 2000).  Initial observations 
made by Hebb in the 1940’s documented that, rats taken from the laboratory 
roaming freely at his house displayed behavioral improvements relative to 
littermates left at the laboratory.  Later on in the 1960’s, Rosenzweig and 
colleagues showed that animals living in a more complex environment showed 
increased brain weight (Bennett et al., 1969).  More recent studies have shown 
EC to increase dendritic branching and length as well as increase the number of 
spines and synapses (Volkmar and Greenough, 1972, Greenough and Volkmar, 
1973).  These findings although reported to occur in various areas of the brain 
such as cortex have been shown to occur in the hippocampus as well (Diamond 
et al., 1976).  Specifically, dendritic density was shown to be increased in the 
dentate gyrus of enriched rats relative to controls (Juraska et al., 1985).  
Similarly, an increase in the number of dendritic spines and dendritic density has 
also been reported in the CA3 region of the hippocampus in response to living in 
a more complex environment (Altschuler, 1979).  These initial anatomical 
 
 22 
findings preceded what has now become a well-documented paradigm for 
studying experience dependent plasticity.  Moreover the power of such 
experience to alter dendritic remodeling is thought to exemplify the ability of the 
brain for self-repair and adapt to change.  Although the mechanisms by which 
such changes occur are yet to be understood, evidence suggests that EC alters 
the expression of plasticity-related genes including growth factors, which could 
participate in the structural and synaptic plasticity changes occurring in the brain 
(van Praag et al., 2000). 
 
In the hippocampus specifically structural plasticity changes in response to EC 
have been associated with increase in growth factors such as NGF (Mohammed 
et al., 1990).  Moreover, besides changing the expression of genes EC has also 
been known to alter hippocampal dentate gyrus synaptic transmission and 
plasticity related events such as increase EPSPs (Green and Greenough, 1986).  
These changes go in parallel with findings showing increase field potentials 
found in the hippocampus of rats housed in a complex environment (Sharp et al., 
1985).   
 
Most of these changes occurring in the hippocampus have been attributed to the 
positive impact of EC on learning and memory. Moreover the fact that EC 
impacts electrophysiological properties of the hippocampus suggest that changes 
in LTP may be occurring to animals housed under EC (Duffy et al., 2001).  Thus 
given that LTP is a well accepted model for learning and memory (Bliss and 
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Collingridge, 1993) it is prudent to hypothesize that changes in LTP occurring in 
the dentate gyrus of rats (Bronzino et al., 1994) may help explain in part the 
improvement in learning and memory occurring in rats exposed to EC. 
 
The initial studies have more recently been followed by studies showing the 
neurogenic effects of EC (Kempermann et al., 1997).  Such increases in 
neurogenesis in the dentate gyrus of the hippocampus have in part been 
attributed to increases in gene expression of growth factors such as VEGF, NGF 
and BDNF (Young et al., 1999, Cao et al., 2004, Zhu et al., 2006). Interestingly, 
behavioral changes in response to EC have also been attributed to increased 
expression of growth factors after EC (Zhu et al., 2006).  Specifically 
improvements in learning and memory have been related to increases in VEGF 
after EC (Cao et al., 2004).  Moreover, changes in behaviors altered in mood 
disorder such as anxiety have also been shown to be improved upon living in a 
more complex environment (Benaroya-Milshtein et al., 2004).  Given the inherent 
ability of EC in promoting cellular and behavioral plasticity in the intact brain, EC 
has gained more attention as a potential tool for studying the recovery of brain 
disorders (Laviola et al., 2008). 
 
Transgenic mouse models have demonstrated that EC has the ability to reverse 
adverse effects of several neurological disorders.  For example EC housing 
ameliorated the spatial memory deficits and delayed the onset of symptoms in an 
animal model of Huntington’s disease (Hockly et al., 2002, Glass et al., 2004).  
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Interestingly, epidemiological results found that a more stimulating environment 
improved physical, mental and social functioning in human Huntington’s disease 
patients (Sullivan et al., 2001).  Furthermore, transgenic mouse models 
containing the human APOE alleles found in Alzheimer’s disease patients have 
also shown improvement in working memory after housing under EC (Levi et al., 
2003).  These behavioral changes were accompanied by an increase in NGF and 
synaptophysin in the hippocampus, suggesting that behavioral changes could 
result from changes in neural plasticity.  The notion that EC may interact with 
genetic manipulations which model disease implies that experience interacts 
profoundly with genetics in altering vulnerability towards disease.  This suggests 
that psychiatric disorders, which are known to have a strong genetic component, 
are subject to experiential manipulation thus altering their degree of onset.   
 
Psychiatric disorders present an extreme challenge given the inherent complexity 
of gene-environment interactions affecting vulnerability to such disorders.  
Although animal models of psychiatric disease present advantages they explicitly 
rely on drug treatment hypothesis for elucidating their characterization.  For these 
reasons it is important to adopt models that encompass the contribution of 
experience and genetic propensity.  Such models of mood disorders may provide 
a better understanding of the neurobiological underpinnings of such disorders. To 
this end I have adopted the use of the High Responder (HR) Low Responder 
(LR) model characterized by individual differences in anxiety-like behavior in 
conjunction with EC. This model should produce a better understanding of the 
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contribution of both experience and genetic predisposition on vulnerability 
towards mood disorders. 
 
High Responder (HR) and Low Responder (LR) Model 
 
The HR and LR model has previously been described as a model of individual 
differences in emotionality.  Early studies carried out by Piazza and co-workers 
demonstrated a relationship between a behavioral response to a novel 
environment and propensity to self-administer drugs of abuse (Piazza et al., 
1989).  When outbred rats are exposed to the mild stress of a novel environment 
high responder (HR) animals exhibit high rates of locomotion while Low 
Responders (LR) exhibit low rates of locomotion (Piazza et al., 1989).  These two 
groups of animals differ in their drug seeking behavior as HR rats learn to self-
administer psychostimulants faster than LR rats (Dellu et al., 1996, Marinelli and 
White, 2000).  
 
Findings show the HR-LR phenotype predicts differences in response to drugs of 
abuse as HR rats exhibit a heightened behavioral sensitization to amphetamine. 
Reports have also found a positive correlation between locomotor response to 
novelty and the magnitude of sensitization to psychostimulants (Hooks et al., 
1991).  Moreover, differences in the acquisition of self-administration have been 
reported between HR and LRs.  For example, HR rats learn to self-administer 
amphetamine more quickly than LR rats (Piazza et al., 1989, Piazza et al., 1990).  
These differences have also been observed in cocaine self-administration as HR 
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learn to self administer low and high doses of cocaine more rapidly than LRs 
(Kabbaj et al., 2001). It is noteworthy that once LRs achieve a stable pattern of 
self-administration their drug-taking behavior becomes indistinguishable from that 
of an HR.  Thus the HR-LR model has certainly become suitable for examining 
individual differences in the initial part of drug-taking behavior. 
 
Current work is aimed at determining the neural correlates underlying the basal 
differences between HR and LR. Such findings could render an understanding of 
the mechanisms that contribute to the vulnerability of drug abuse.  Initial work 
focused on differences in Dopamine (DA) responses, with HR showing greater 
DA response relative to LR (Piazza et al., 1991).  These findings included basal 
and stress related DA responses (Rouge-Pont et al., 1993) which are 
modulatable by glucocorticoids (Piazza et al., 1996). Interestingly, HRs show a 
more profound release of glucocorticoids in response to stress (Kabbaj et al., 
2000). 
 
However, more recent work by our laboratory has highlighted the importance of 
other neural mechanisms contributing to the phenotypic differences.  Specifically 
our laboratory has rendered the importance of stress molecules associated with 
HR-LR differences, as stress is an inherent component of the novelty response 
and a critical factor in vulnerability to drug taking behavior.  Findings along these 
lines demonstrated HR-LR differences in the expression of several stress related 
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genes such as CRH in the amygdala and hypothalamus, and glucocorticoid 
receptor in the hippocampus (Kabbaj et al., 2000).   
 
Anatomical profiling using immediate early gene expression of c-fos has also 
enabled the characterization of neural activation in HR-LR in response to mild 
stressors.  Relative to LRs, HRs show low expression of c-fos in the CA1 region 
of the hippocampus, while showing high expression in the olfactory area, orbital 
cortex, cingulate cortex, dorsal striatum and the paraventricular nucleus of the 
hypothalamus (Kabbaj and Akil, 2001).  Given that c-fos is a transacting factor 
that alters the expression of other genes, it seems possible that HR-LR might 
show different long-term responses to stress as evidenced by their different 
immediate early gene expression response in different anatomical regions. Thus, 
experiences may render different neural consequences in HRs and LRs, which 
could translate into differences in emotional reactivity in both phenotypes.  
Indeed it has been shown that stress differentially alters HR and LR drug-taking 
behavior.  Thus while HRs typically self-administer drugs more readily relative to 
LRs, after social defeat stress the scenario is dramatically different as HR 
animals appear inhibited (Kabbaj et al., 2001).  Thus, repeated social defeat 
stress, which is known to enhance drug-taking behavior, results in a transient 
inhibition of self-administration in HRs followed by a return to normal drug talking 
behavior.  On the other hand, LR animals, which typically show little response to 
drugs, respond in the opposite manner by showing a dramatic increase in self-
administration thus becoming indistinguishable from HRs. Taken together the 
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HR-LR model reliably demonstrates that stressful experiences may differentially 
impact individual drug taking behavior.  Moreover, the differential neural 
responses observed in HRs and LRs in response to mild stress suggest that 
different neural mechanisms may underlie the propensity for drug taking 
behavior; where in some animals (LR) drugs are seek in response to stress, 
whereas in others drug-seeking is due to their propensity for novelty response.    
 
Although the initial characterization of these phenotypes was revealed in the 
context of vulnerability towards drug taking behavior, more recently the HR-LR 
model has provided insight on the neural correlates associated with emotional 
stress responsiveness to the environment (Piazza et al., 1989, Dellu et al., 1996).  
Our laboratory has shown that these differences in locomotor response to novelty 
also predict differences in anxiety-like behavior (Kabbaj et al., 2000) (Kabbaj and 
Akil, 2001), with HR animals exhibiting lower levels of anxiety behavior in the 
light-dark box test and Elevated Plus Maze (EPM) relative to LRs.  Thus, HR 
animals seem to display high exploration on novel environments that may be 
considered mildly stressful.  Moreover, these behavioral differences are also 
accompanied by differences in corticosterone stress responses where HRs 
exhibit a more prolonged corticosterone response. These different endocrine 
responses are attributed to differences in the negative feedback regulation of the 
HPA axis as HR animals show lower levels of GR expression in the hippocampus 
relative to LRs.  However, it is important to note that such basal differences in 
anxiety-like behavior are also subject to experiential influence, as seen earlier 
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with drug taking behavior.  For example if HRs are socially isolated their behavior 
becomes indistinguishable from that of an LR thus showing a more inhibited 
anxious-like phenotype (Kabbaj et al., 2000).  Similarly, when a stressor is 
imposed such as in restraint stress the low anxiety HR behavioral phenotype 
disappears.  Thus, these results imply that basal HR-LR differences in anxiety-
like behavior are also modulated by experiences that may lead to differential 
changes in gene expression.  Such experiences in turn may translate into 
changes in the expression of genes associated with neural plasticity such as 
FGF-2. 
 
Finally, while much of this literature has relied on outbred animals, our laboratory 
has embarked on an ongoing selective breeding project (now in the 19th 
generation).  This selective breeding project has demonstrated that these 
behavioral phenotypes are highly heritable.  The knowledge gained from our 
selectively bred HRs and LRs has shown that novelty response is a genetically 
heritable trait, which can reliably predict individual differences in anxiety-like 
behavior.  This provides an advantage for ascertaining neural correlates 
associated with HR-LR differences in anxiety-like behavior.  Furthermore the HR-
LR selective breeding project provides a model profiting heavily from genetic 
homogeneity, thus enabling us to better study differences in the propensity 




Elucidating the mechanisms by which experience can interact with genetic 
predisposition to control emotional reactivity is fundamental for understanding 
normal behavior and for explaining the etiology of mood disorders.  Clearly, 
adverse stressful experience has been identified as one of the main epigenetic 
factors leading to the onset of mood disorders (Lopez et al., 1999).  As a result 
much effort has focused on the impact of stress on brain structure and function 
as well as on emotional responsiveness.  However, most of these studies have 
focused on stressors that are aversive, uncontrollable and generally negative for 
the animal. Less is known about the impact of other environmental manipulations 
on emotionality, including changes in the environment that might be considered 
either positive or at least more complex in their valence such as in EC.  This 
dissertation focuses on this latter class of environmental experience and 
examines the potential role of FGF-2 in this process.  Based on reports 
mentioned above I hypothesize that; High levels of hippocampal FGF-2 
brought by genetic inheritance or environmental complexity contribute to 
reduce anxiety-like behavior. 
  
To this end, in my first chapter we examined the link between changes in 
hipocampal FGF-2 gene expression, anxiety behavior and hippocampal cell 
genesis observed after environmental complexity. These initial studies 
investigated whether changes in hippocampal cell genesis and anxiety behavior 
seen after EC were dependent on the FGF system activity.  Following these 
studies chapter 2 examined the direct role of the endogenous hippocampal FGF 
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system on anxiety behavior by examining the impact of an FGF antagonist on 
anxiety. In addition I also investigated the specific role of FGF-2 on anxiety by 
looking at its impact on selectively bred HR-LR animals, a model characterized 
by genetically inherited differences in anxiety-like behavior.  Finally, we conclude 
this dissertation by examining the role of FGF-2 in mediating the gene-
environment interaction on vulnerability to anxiety.  Specifically I investigated 
how FGF-2 can serve as a protective agent on individual vulnerability to anxiety 
as brought by genetic endowment, as seen in HR-LR, or from environmental 
influence, as seen after EC.  Finally, I end this thesis project by investigating the 
role of hippocampal cell genesis as a potential mechanism mediating the 
influence of FGF-2 on vulnerability to anxiety behavior. 
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Chapter 2  
 
FGF-2 is required for the beneficial effects of 





Emotionality refers to the unique constellation and magnitude of the endocrine, 
neural and behavioral responses of an organism when exposed to environmental 
stimuli that have valence be it negative or positive.  The hippocampus is one of 
the key brain structures that modulate these responses.  Exposure to sustained 
stress increases anxiety-like behavior and can lead to various structural changes 
in the hippocampus, including disruption of adult neurogenesis. In contrast 
Environmental Complexity (EC), a behavioral paradigm involving communally 
housed animals exposed to various objects and toys, has been shown to 
enhance neurogenesis and reduce anxiety-like behavior. Previous findings 
showing decreased levels of FGF-2 expression in brains of postmortem subjects 
that suffered from major depression have implicated the FGF system as a novel 
target modulating vulnerability to mood disorders.  However, the extent of such 
findings has yet to be linked to behavioral measures of emotionality.  Given that 
altered anxiety is observed in mood disorders such as depression we examined 
the potential contribution of FGF-2 on the anxiolytic and neurogenic effects of 
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EC.   Our results showed that EC increased FGF-2 gene expression and 
neurogenesis in the hippocampus. EC reduced anxiety-like behavior in the 
novelty suppressed feeding test, extending previous findings that used other 
measures of anxiety behavior.  Interestingly, when animals were administered 
with an FGF receptor antagonist during exposure to EC we saw a disruption in 
the anxiolytic effects of EC.  These effects were paralleled by changes in 
hippocampal cell genesis as FGF blockade disrupted the effects of EC on 
increasing cell proliferation and new cell survival.  Taken together our results 
suggest that hippocampal FGF-2 is required for the anxiolytic effects of EC, and 





While genetic endowment may confer either vulnerability or protection towards a 
high level of emotional reactivity and stress responsiveness, environmental 
factors are also thought to play a critical modulating role.  In particular, stressful 
experiences are known to alter emotionality, and are often recognized as the 
trigger for episodes of severe mood disorders.  However, less is known about the 
protective consequences of the environment and experience on emotionality. 
One particular paradigm well known for showing the protective consequences of 
the environment on emotionality is Environmental Complexity (EC).  Specifically, 
EC has been shown to reduce anxiety behavior (Benaroya-Milshtein et al., 2004). 
Moreover, EC has been reported to improve learning and memory and enhance 
hippocampal neurogenesis, (Nilsson et al., 1999) a phenomenon regarded as a 
key mechanism by which antidepressants exert their behavioral effects on animal 
models of mood disorders (Santarelli et al., 2003). 
 
It has been well documented that stress has detrimental effects on emotional 
behavior and decreases hippocampal neurogenesis (Gould et al., 1997, Tanapat 
et al., 1998, Malberg and Duman, 2003, Mirescu et al., 2004).  Moreover, the 
effects of such stressful experiences are reversed by antidepressant treatment 
(Malberg and Duman, 2003).  Since antidepressants represent an effective 
treatment strategy, their mechanisms of action have been used as a point of 
departure for understanding the etiology of mood disorders (Jacobs, 2002).  
Thus, increased adult neurogenesis has been suggested as one of the 
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mechanisms by which antidepressants exert their beneficial effects on behavioral 
measures of anxiety (Santarelli et al., 2003). 
Studies on the neural and behavioral effects of antidepressants have mostly 
focused on Brain Derived Neurotrophic Factor (BDNF) (Duman, 1998, Shirayama 
et al., 2002, Duman, 2004).  However, recent studies involving our research 
group have shown a down-regulation of FGF-2 in the brains of post mortem 
subjects with major depression (Evans et al., 2004).  Moreover, reports have also 
shown that antidepressant treatment increases FGF-2 expression in the rat 
hippocampus (Mallei et al., 2002).  These findings led us to the hypothesis that 
decreased levels of FGF-2 may be involved in the pathophysiology of severe 
depression and the closely associated increase in anxiety, and that 
antidepressants and anxiolytic drugs may exert their effects by increasing FGF-2 
(Turner et al., 2006, Akil et al., 2008). 
 
FGF-2 is a member of the FGF gene family composed of 24 proteins that have 
multiple functions including development of the nervous system and 
angiogenesis (Eckenstein et al., 1991).  In the adult, FGF-2 shows prominent 
expression in astrocytes throughout the brain, whereas neuronal expression is 
almost exclusive to the hippocampus (Woodward et al., 1992).  FGF-2 exerts its 
function by interacting with four receptor types with varying affinity depending on 
ligand and receptor isoforms (Ornitz, 2000, Reuss and von Bohlen und Halbach, 
2003).  These receptors are trans-membrane glycoproteins containing three Ig-
like loops (I-II-III) in the extracellular domain and a split tyrosine kinase domain.  
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Three of the FGF receptors, FGFR1, FGFR2 and FGFR3, are expressed in the 
brain (Eckenstein, 1994), while FGFR1 is most abundantly expressed in the 
hippocampus (Belluardo et al., 1997).  These receptors are expressed in both 
neurons and glial and may participate in glial and neuronal signaling interactions 
that may have important implications during development as FGFR1 has 
previously been shown to be required for hippocampal growth (Ohkubo et al., 
2004).   
 
FGF-2 has mostly been recognized for its mitogenic and survival effects on adult 
stem cell cultures derived from numerous areas of the central nervous system 
(Palmer et al., 1999).  However, these neurogenic effects have only been 
reported in vivo during certain developmental periods.  For example single 
peripheral injections of FGF-2 have been shown to enhance hippocampal 
neurogenesis in young rodents, yet these effects were not observed in the adult 
(Wagner et al., 1999).  However, repeated exogenous administration with FGF-2 
has been shown to rescue age related declines of hippocampal neurogenesis 
(Rai et al., 2007).   
 
While evidence implicating FGF-2 in emotional behavior is limited, studies 
suggest that at least during development, there may be an important interplay 
between emotional experiences and FGF2 expression. For example; rats that 
were raised by mothers who exhibited better care for their pups showed higher 
protein levels of FGF-2 and enhanced survival of neurogenesis during adulthood 
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(Bredy et al., 2003).  Since rats that receive increased maternal care show 
reduced endocrine stress responses and better adaptive behaviors towards 
environmental challenges (Francis and Meaney, 1999, Menard et al., 2004), this 
might suggest an association between higher FGF-2 levels and lower anxiety 
behavior. Conversely, prenatal stress has been shown to reduce both basal 
levels of FGF-2 and neurogenesis (Coe et al., 2003) in the hippocampus of adult 
rats (Molteni et al., 2001). Interestingly, the behavioral and endocrine deficits 
resulting from prenatal restraint stress as well as the associated decrease in 
neurogenesis have been reversed by EC (Morley-Fletcher et al., 2003, Laviola et 
al., 2004). Similarly, deficits in hippocampal development resulting from 
decreased maternal care have been shown to be rescued by EC (Bredy et al., 
2004). Together, these studies suggest that during development, both positive 
and negative environmental factors (stress, maternal care, environmental 
enrichment) can exert lifelong impact on both emotionality and hippocampal 
function, including neurogenesis, in the adult animal. They also suggest that 
some of these effects are associated with altered levels of FGF-2 during 
development.  However, they do not firmly establish a causal role of FGF-2 in 
mediating environmental influences on emotional reactivity. 
 
However, it remains unclear whether FGF2 is relevant only during a certain 
developmental time window or whether it plays a key role during adulthood in 
encoding environmental influences and mediating changes in emotional 
responses. While the human postmortem studies uncovered a decrease in FGF-
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2 in severe depression, it was difficult to ascertain whether this was due to a 
genetic predisposition that was present throughout the patient’s life, the impact of 
the illness itself, or some combination of factors.  
 
Thus, in this chapter I asked whether a non-aversive experience that can 
decrease anxiety in the adult animal (EC) can also modulate FGF-2 expression. 
Moreover, we directly test the idea that this alteration in FGF-2 expression is not 
simply a byproduct of the environmental change, but plays a causative role in the 
associated change in anxiety behavior. 
 




Adult Male Sprague-Dawley rats were obtained from our in-house breeding 
colony at the Molecular and Behavioral Neuroscience Institute (MBNI) where we 
have maintained the selectively bred HR-LR lines for over 18 generations. Adult 
rats (300g-400g) around 2 months old were housed two animals per cage (one 
HR, one LR per cage to balance out potential intergroup variance) after 
locomotor screening under a 12 hr light/dark cycle (lights on at 6:00 am) with 
food and water available ad libitum.  Animals were allowed to acclimate to the 
housing conditions for at least 7 days prior to any experiments.  All animals were 
treated in accordance with the National Institutes of Health guidelines on 
laboratory animal use and care and in accordance with the guidelines set by the 
 
 49 





At postnatal day 55-60, adult male rats were screened for locomotor response to 
a novel environment by placing them in a standard size (43×21.5×24.5) clear 
acrylic cage in a different room from where the animals had been housed. 
Locomotor activity was monitored every 5 minutes for 1 hour by two panels of 
photocells connected to a computer. The first panel of three photocells was 
placed at ground level to record horizontal locomotion, with the second panel of 
five photocells located near the top of the cage to determine rearing behavior. 
The locomotion testing rig and motion recording software were created in-house 
at the University of Michigan. Locomotion activity was tested between 9:00 and 





Rats were housed for 21 days in 3 × 3 × 3 ft stainless steel cages which 
contained different toys, obstacle courses, and enriching stimuli.  Every day, 





Novelty Suppressed Feeding Test 
 
Rats were food deprived for 18 hrs prior to testing.  On the next morning, animals 
were placed in an open field for a maximum of 5 minutes with a food pellet 
placed in the middle of the open field, and the latency to grab and start eating the 
food pellet was used as a measure of anxiety.  
 
mRNA in situ Hybridization 
 
At the conclusion of each experiment, rats were sacrificed by rapid decapitation, 
and their brains were removed, snap frozen, and stored at -80 ºC.  Brains were 
cryostat sectioned at -20°C at 20µm and sliced in series throughout the 
hippocampus, mounted on Super Frost Plus slides (FisherScientific) and stored 
at -80°C until processed. In situ hybridization methodology has been previously 
described in detail elsewhere (Kabbaj et al., 2000).  Sections taken every 100µm 
were fixed in 4% paraformaldehyde at room temperature for 1 h, and then 
washed three times in 2X SSC. Slides were processed in a solution containing 
acetic anhydride (0.25%) in triethanolamine (0.1 M, pH 8.0) for 10 min, rinsed in 
distilled water, dehydrated through graded ethyl alcohols (50, 75, 85, 95 and 
100%) and then air dried, all at room temperature. After air-drying, the sections 
were hybridized with a 35S-labeled cRNA probe for FGF-2.  The sequences of rat 
mRNA used for generating probes of genes are complementary to the following 
RefSeq database nos FGF2 (NM_019305, 716-994), and the probe was 
synthesized in our laboratory.  All cDNA segments were extracted (Qiaquick Gel 
Extraction Kit, Qiagen, Valencia, CA), subcloned in Bluescript SK (Stratagene, 
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LA Jolla,CA ) and confirmed by nucleotide sequencing. The FGF-2 probe was 
labeled in a reaction mixture consisting of 1 µg of linearized plasmid, 1X 
transcription buffer (Epicenter Technologies, Madison, WI), 125 µCi of 35S-
labeled-UTP, 125 µCi of 35S-CTP, 150 µM ATP and GTP, 12.5 µM dithiothreitol, 
0.5 ml of RNase inhibitor, and 1.5 µl of T3 RNA polymerase.  The reactions were 
incubated for 120 min at 37ºC, and then 1 µl of DNAse (RNAse free) was added 
to the reaction to incubate for another 15 min at room temperature.  The labeled 
probes were purified using Micro Bio-Spin P-30 Tris Spin Columns (Bio-Rad 
Laboratories), then diluted in hybridization buffer (containing 50% formamide, 
10% dextran sulfate, 3XSSC, 50 mM sodium phosphate buffer, pH 7.4, 
1XDenhardt’s solution, 0.1 mg/ml yeast tRNA, and 10 mM dithiothreitol) to yield 
106 dpm/70 µl.  A cover slip with 70 µl of diluted riboprobe was placed on each 
slide.  Slides were placed in a humidified box with filter paper saturated with 50% 
formamide buffer, and incubated overnight at 55°C.  Following overnight 
incubation, the coverslips were removed, rinsed, and washed twice in 2X SSC for 
5 min each. The sections were treated for 1 h in RNAase A solution (20 µg/ml in 
Tris buffer containing 0.5 M NaCl, pH 8) at 37°C. Following treatment, the 
sections were washed in increasingly stringent solutions of SSC, 2X, 1X and 
0.5X, for 5 min each. The slides were then incubated for 1 h in 0.1X SSC at 
65°C. Finally the sections were rinsed with water and dehydrated through graded 
alcohols, air-dried, and exposed to a Kodak XAR film (Eastman Kodak, 
Rochester, NY, USA). Exposure time of 7 days was experimentally determined to 
maximize signal for the FGF-2 probe.  The films were developed (Kodak D-19; 
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Eastman Kodak, Rochester, NY, USA), and brain section images were captured 
from film with a CCD camera (TM-745, Pulnix) using MCID and relative optical 
densities were determined for each section. Radioactive signals were quantified 
using computer-assisted optical densitometry software (Scion Image Beta 4.03; 
Scion Corporation, Frederick, MD). Integrated densities were found by outlining 
the region of interest from both hemispheres. Optical density measurements 
were corrected for background, and the signal threshold was defined as the 
mean gray value of background plus 3.5× its standard deviation. Only pixels with 
gray values exceeding the above-defined threshold were included in the analysis.  
Optical density measurements were taken for 4 subregions of the hippocampus 
(hippocampal fields CA1-CA3, and the dentate gyrus) from the left and right 
sides of the brain. Data from multiple sections per animal were averaged 
resulting in a mean integrated optical density value for each animal and then 
averaged for each group. 
 
Surgeries and Microinjections 
 
Rats were anesthetized using isoflurane before surgery and a single cannulae 
(22-gauge, Plastics One Inc., VA. USA) was implanted into the left lateral 
ventricle (coordinates from bregma: AP -.9; ML +1.3; DV -1.8) using a stereotaxic 
apparatus. The guide cannulae were anchored to the skull and fitted with an 
obdurator.  Obdurators were removed and 28-gauge injector cannulae were 
inserted extending 1.5mm below the tip of the guide.  The cannulae were 
connected by PE-20 tubing to a Hamilton syringe mounted on a syringe pump 
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(Harvard Apparatus, MA. USA). Rats were microinjected with 100nM dose of the 
FGF receptor antagonist PD173074 (Pfizer) dissolved in artificial cerebrospinal 
fluid (aCSF) or vehicle three times a week for 21 days throughout the duration of 
the EC training period. Total volume of 5ul was infused at a rate of 1.0µl/min, and 
the injector was left in place for an additional 2 min to allow diffusion of the drug. 
Animals were subjected to behavioral testing 24 hours after the last injection.  
Rats were killed by decapitation and the brains were snap frozen in isopentane 
after behavioral testing.  
 
BrdU/ Ki67 Immunohistochemistry 
 
To assess the effect of EC on hippocampal new cell survival, rats were injected 
with Bromodeoxyuridne (BrdU) (Calbiochem) for two days prior to the start of 
training paradigm at a dose of 200mg/kg dissolved in saline.  Twenty-four hours 
post BrdU labeling animals underwent 21 days of EC before being exposed to 
behavioral testing after which they were sacrificed by decapitation and brains 
were snap frozen.  For determining the rate of cell proliferation we performed 
immunohistochemical labeling of Ki-67, which is an endogenous marker of 
ongoing cell proliferation. For BrdU and Ki67 imunohistochemistry a series of 
every 8 sections was cut throughout the entire extent of the hippocampus at 30 
µm and slide mounted.  For Ki-67 DAB staining, sections were postfixed in 4% 
paraformaldehyde for 1hr, followed by a 45 minute incubation in 10mM sodium 
citrate at 90°C.  Sections were then rinsed with PBS and washed in 0.3% 
peroxide followed by blocking with BSA containing 1% goat serum and 0.05% 
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Triton X-100.  Subsequently sections were incubated overnight with rabbit 
polyclonal anti-ki67 (University of Michigan) 1:40000 in BSA.  After PBS washes 
sections were then incubated in biotinylated goat anti rabbit secondary antibody 
1:1000, (Vector labs) followed by Avidin/Biotin complex (Vectastain Elite ABC kit) 
and subsequent DAB reaction for visualization of signal.  For DAB staining of 
BrdU, sections were postfixed in 4% Paraformaldehyde for 1hr, rinsed in PBS 
and washed in 0.3% peroxide.  Sections were then incubated in 50% formamide-
2X SSC at 65°C for 2 hours followed by two 5 minute rinses in 2X SSC.  Slides 
were then placed for 30 minutes in 2N HCL at 37°C and 10 minutes in 0.1M Boric 
Acid at room temperature, followed by rinsing in PBS and blocked with BSA 
containing 1% goat serum and 0.05% Triton X-100.  Sections were incubated 
overnight at room temperature with rat monoclonal anti-BrdU (Accurate) 1:1000 
in BSA. After PBS washes sections were then incubated in biotinylated goat anti 
rat (Vector labs) secondary antibody 1:1000 followed by Avidin/Biotin complex 
amplification (Vectastain Elite ABC kit) and subsequent DAB reaction for 
visualization of signal. Cresyl violet staining was performed for both immuno 
stains and sections were subsequently dehydrated through graded alcohols 





For quantification of DAB stained Ki-67 and BrdU cells, slides were initially coded 
and the code was not broken until counts were analyzed to assure that a blind 
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observer performed cell counts.  To estimate the total number of cells we 
followed a modified unbiased stereological procedure used by (Malberg and 
Duman, 2003) where the total number of cells counted per animal was multiplied 
by the reciprocal of the sampling factor.  BrdU and Ki67 cells were counted in the 
granule cell layer and SGZ of the hippocampus on a light microscope under 63X 
objective.  Cells were included in SGZ counts if the cell was near the SGZ or 
touching the SGZ and was excluded if the cell was more than two cell diameters 




Behavioral studies and anatomical studies were analyzed by Student t-tests or 
ANOVAs followed by Fishers PLSD post-hoc test comparisons. All data are 





Environmental Complexity increases FGF-2 gene expression in the 
hippocampus and reduces anxiety like behavior.   
 
To begin to elucidate whether hippocampal FGF-2 expression responds to 
experiences known to reduce anxiety such as Environmental Complexity (EC) we 
examined hippocampal FGF-2 gene expression in animals that were exposed to 
EC or standard housing conditions.  I focused on the hippocampus as FGF-2 
shows prominent neuronal expression in this area, and since enhanced 
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hippocampal neurogenesis has been observed after EC.   As seen in Figure 2-1, 
EC training results in an overall significant increase in FGF-2 expression in the 
dentate gyrus, [t(21)=4.53, p<0.001], CA3 region, [T(21)=3.5, p<0.01], and CA1 
region, [t(21)=5.6, p<0.0001] whereas no significant effects where observed in the 
CA2 region [t(21)=0.23, p=0.82].  Furthermore, as seen in Figure 2-2., EC 
decreased anxiety as shown by a decrease in the latency to feed on the novelty 
suppressed feeding test [t(20)=-2.2, p<.05].  These results were specific to the 
novelty arena as no differences were observed in home cage feeding [T(20)=1.6, 
p>.05] 
 
Environmental Complexity increases cell proliferation and new cell 
survival. 
 
Although EC had previously been linked to an increase in neurogenesis we 
wanted to verify whether such changes paralleled the increase in FGF-2 
expression seen earlier in response to EC on our experimental conditions.  As 
seen in Figure 2-3., EC exposure results in a significant increase in cell 
proliferation in the dentate gyrus as shown by an increase in the number of Ki67 
labeled cells, [t(15)=2.8, p<0.05].  Moreover, there was also an increase in the 
survival of newly born cells in the dentate gyrus as measured by the number of 





FGF receptor antagonism blocks the effects of Environmental Complexity 
on increasing cell proliferation and survival. 
 
Given that EC led to a significant increase in FGF-2 gene expression in the 
dentate gyrus and enhanced cell genesis, we asked whether FGF-2 played a 
causative role in the change in neurogenesis.  Thus, we used chronic treatment 
with an FGF receptor antagonist to test whether it was sufficient to block the 
effects of EC on increasing cell genesis in the hippocampus.  
As shown in Figure 2-4., under vehicle conditions, EC results in a significant 
increase in cell proliferation and cell survival as shown by an increase in the 
number of Ki67 [F(1,8)=5.8 p<0.05] and BrdU cells [F(1,8)=10.6, p<0.01] 
respectively.  On the other hand when animals were treated with an FGF 
receptor antagonist, EC failed to significantly increase cell proliferation 
[F(1,8),=2.2, p=0.20] and new cell survival [F(1,8)=2.1, p=0.20]. These results 
suggest that FGF receptor activation is required for EC to induce an increase in 
cell genesis in the dentate gyrus of the hippocampus and that the FGF system 
might contribute to the neurogenic effects of EC. 
 
FGF receptor antagonism blocks the anxiolytic effects of Environmental 
Complexity. 
 
Given that we had seen that EC resulted in an increase in FGF-2 expression and 
a decrease in anxiety we aimed to determine whether FGF receptor activation 
was required for EC to reduce anxiety.  For these experiments we used an FGF 
receptor antagonist PD173074 (Pfizer), which was injected 3 times a week 
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throughout the duration of the EC training period.   As seen earlier in our results 
and in part A. of Figure 2-5., under normal conditions EC animals respond with a 
significant decrease in anxiety as shown by a decrease in the latency to feed 
[T(20)=-2.2, p<0.05].  On the other hand, when EC animals are treated with an 
FGF antagonist this significant change in anxiety behavior in lost.  Thus, FGF 
receptor blockade results in a disruption of the anxiolytic effects of EC [T(16)=0.8, 
p>.05].  Taken together these results suggest that FGF receptor activation is 




The present study evaluated the potential role of FGF-2 to modulate the effects 
of experience on anxiety and neurogenesis. Using enrichment as a model of an 
environmental manipulation that is construed as neuroprotective, we determined 
whether FGF-2 was impacted by experience in the adult brain, and whether in 
turn this growth factor played a direct role in experience-dependent modulation of 
anxiety-like behavior and hippocampal neurogenesis.  As previously reported, 
our demonstrate show that exposing animals to a more complex environment, as 
opposed to standard housing conditions, results in a decrease in anxiety-like 
behavior. Moreover, it increases the generation of new hippocampal cells by 
enhancing cell proliferation and cell survival.  Importantly, we demonstrated that 
the exposure to a complex environment was accompanied by a significant 
increase in FGF-2 gene expression in the hippocampus. It was therefore 
reasonable to ask whether this increase in FGF-2 expression played a role in the 
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behavioral and/or neurogenesis alterations resulting from exposure to EC. This 
was tested by administering an FGF receptor antagonist to block the effect of the 
rise in endogenous FGF-2, and to determine whether this would prevent the 
neural and behavioral effects of EC. Our findings suggest that this treatment 
produced a blockade on the effects of EC in cell proliferation and cell survival.  
Moreover, treatment with the FGF receptor antagonist resulted in the disruption 
of the anxiolytic effects of EC.  Taken together our results suggest that FGF-2 
plays a key role as a neural modulator of the protective effects of experience on 
anxiety and hippocampal cell genesis. 
 
The ability of EC to enhance neurogenesis has been reported previously 
(Kempermann et al., 1997) (Nilsson et al., 1999), and has been regarded as part 
of an overall beneficial response of hippocampal circuitry to this treatment (van 
Praag et al., 2000).  Changes in cell genesis in the hippocampus have led to 
intense debate about their relevance to overall hippocampal function, particularly 
as it relates to the underlying mechanisms of mood disorders (Duman and 
Monteggia, 2006).  For example stress, which is regarded as a robust trigger of 
depressive episodes has been shown to decrease proliferation and survival of 
adult stem cells (Gould et al., 1997), whereas antidepressant treatment has been 
shown to increase neurogenesis (Malberg et al., 2000). Furthermore, 
neurogenesis has been proposed as being critical to the behavioral effects of 
antidepressants (Santarelli et al., 2003).  These reports along with others have 
prompted the hypothesis that decreased neurogenesis might in part be the 
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underlying mechanism of affective disorders (Warner-Schmidt and Duman, 
2006).  Nevertheless, these studies are largely correlational as it is difficult to 
manipulate the rate of cell birth, cell survival or cell differentiation in the 
hippocampus in a selective manner, and ascertain the functional impact on any 
given behavior.  However, there is great advantage in determining some of the 
triggers of neurogenesis, and being able to modulate them and study their impact 
on behavior.  
 
Growth factors such as FGF-2 have been shown to respond to antidepressant 
treatments (Mallei et al., 2002) and shown to be differentially down regulated in 
post mortem brains of depressed subjects (Evans et al., 2004).  Furthermore, 
FGF-2 has been shown to enhance neurogenesis in the hippocampus when 
administered exogenously (Wagner et al., 1999, Rai et al., 2007).  Thus, it is 
reasonable to hypothesize that FGF-2 might be one of the factors that might 
modulate the rate of neurogenesis.  However, the role of endogenous FGF-2 in 
the adult hippocampus had not been extensively studied, either as a modulator of 
neurogenesis or as a regulator of emotional responsiveness. 
 
Our initial results support the notion that increased hippocampal FGF-2 gene 
expression induced by EC could participate in the modulation of cell proliferation 
and cell survival.  This was further supported by our second set of experiments, 
which showed that when animals were administered concomitantly with an FGF 
receptor antagonist during exposure to EC, the increased proliferation and 
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survival response was partially disrupted.  These results support the role of FGF-
2 as a modulator of EC’s effect on increasing cell genesis.  This is supported by 
findings showing the same FGF receptor antagonist compound blocking the 
increase cell proliferation responses of FGF-2 in vitro (Skaper et al., 2000).  
Furthermore, they point to FGF-2 as being necessary for EC to increase 
hippocampal cell genesis.    
 
Although our results point to FGF-2 as being a key player in modulating EC’s 
effects on increasing cell genesis it is difficult to ascertain whether the antagonist 
treatment reflects a blockade in FGF-2 activity.  Although this drug has been 
shown to be specific for FGF receptors (Bansal et al., 2003), this compound does 
not necessarily discriminate on which FGF receptor it acts, as it binds to the 
tyrosine kinase domain of all FGF receptors (Mohammadi et al., 1998).  This 
suggests that this compound has the potential to act on many different FGF 
receptor isoforms, including those, which show high and low affinity for FGF-2 
binding and activation.  Three of the four FGF receptors are expressed in the 
brain, each with at least 2 isoforms identified, thus a diverse number of receptors 
could be targeted.  Furthermore, many more FGF ligands are expressed in the 
brain all with different binding affinity and efficiency response to each of the 
receptors (Ornitz et al., 1996). This makes for a plethora of FGF ligand receptor 
interacting combinations that could be targeted and disrupted in response to the 
antagonist.  Conversely it is known that FGF receptor 1 is most abundantly 
expressed in the hippocampus whereas FGFr2 and FGFr3 show a more diffuse 
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expression within the white matter (Belluardo et al., 1997).  Furthermore, as we 
saw FGF-2 increases significantly in the hippocampus in response to EC and 
both FGF-2 and FGFr1 have been shown to have a key role in hippocampal 
neurogenesis (Ohkubo et al., 2004) (Cheng et al., 2002).  Finally, reports suggest 
that FGF-2 seems to have a preferential efficiency response in proliferation when 
interacting with FGF receptor 1 as opposed to FGFr2 and FGFr3 (Reuss and von 
Bohlen und Halbach, 2003) (Ornitz et al., 1996).  Thus while it is possible to 
suspect that the effects of the antagonist could be attributed to other FGF ligands 
our results strongly implicate FGF-2 as mediator of the effects of EC on 
increasing cell genesis.  
 
Our results also point to FGF-2 as an active mediator of the effects of EC on 
decreasing anxiety-like behavior.  This is supported by evidence showing the 
FGF receptor antagonist blocking the anxiolytic effects of EC on the novelty 
suppressed feeding test. As seen in our results under baseline conditions EC 
strongly reduces anxiety, whereas in the presence of an FGF receptor antagonist 
treatment this difference disappears. These results strongly implicate the FGF 
system as an important player in the anxiolytic effects of EC.  
 
Although other studies have shown other growth factors such as VEGF and 
BDNF modulating emotional behavior (Shirayama et al., 2002, Warner-Schmidt 
and Duman, 2007) this is the first time the FGF system is implicated in 
experience dependent modulation of emotional behavior.  FGF-2 has previously 
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not been linked to anxiety, however, FGF-2 is well known for responding with 
changes in gene expression particularly in the hippocampus in answer to 
experiences and pharmacological treatments known to modulate anxiety-like 
behavior.  For example hippocampal FGF-2 gene and protein expression 
increases in response to chronic antidepressants (Mallei et al., 2002) and acute 
treatments with diazepam (Gomez-Pinilla et al., 2000) both of which are known to 
reduce anxiety-like behavior. On the other hand FGF-2 gene expression in the 
hippocampus is also decreased after anxiogenic experiences including social 
defeat (Turner et al., 2008), in prenatal stress (Fumagalli et al., 2005) and 
decrease maternal care (Caldji et al., 1998, Bredy et al., 2003).  Interestingly, EC 
has been shown to reverse the anxiogenic effects of maternal separation 
(Francis et al., 2002).  However, it is yet to be determined whether such changes 
are due to increased FGF-2 expression in the hippocampus. Given our findings 
along with the previous reports we hypothesize that FGF-2 is an essential 
mediator of experience dependent anxiety behavior. 
The mechanism by which FGF-2 may modulate experience dependent anxiety is 
yet to be determined.  One hypothesis of depression states that neurotrophic 
factors and neurogenesis are critical players in mediating the behavioral 
responses of antidepressants and suggests that growth factors mediate the 
antidepressant behavioral responses by increasing neurogenesis in the 
hippocampus (Schmidt and Duman, 2007).  In support of this hypothesis, there 
are data showing FGF-2 expression increased in the hippocampus after 
antidepressant treatment (Mallei et al., 2002) as well as evidence showing FGF-2 
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positively modulating hippocampal neurogenesis (Pieper et al., 2005).  Given that 
EC shows similar effects on both increasing neurogenesis and reducing anxiety, 
we hypothesized that EC could work via the same mechanism.   The likelihood 
that FGF-2 mediates the anxiolytic effects of EC via neurogenesis is supported 
by our findings, which show an FGF receptor antagonist to blocking the increase 
in cell genesis after EC, while blocking the anxiolytic effects of EC.  However, our 
results do not rule out the possibility that FGF-2 may act by other mechanisms of 
plasticity such as increasing dendritic arborization given that EC has been shown 
to reduce anxiety independent of neurogenesis (Meshi et al., 2006) and FGF-2 
has been shown before to promote dendrite outgrowth in the hippocampus (Rai 
et al., 2007).  This would be especially plausible given that not only has EC 
previously been shown to promote such plasticity in several brain areas including 
the hippocampus, but other aversive experiences which increase anxiety such as 
stress (Wood et al., 2008) have been shown to have opposite effects (Watanabe 
et al., 1992). 
 
In conclusion we present for the first time that the FGF system is an important 
modulator of the impact of EC on decreasing anxiety and hippocampal cell 
genesis. These results support the role of the FGF system as a modulator of 
experience dependent anxiety-like behavior pointing to FGF-2 as a potential 
candidate mediating EC’s impact on anxiety. Although, our results suggest that 
EC requires FGF receptor activity for its anxiolytic impact there cannot be a direct 
comparison between the baseline and antagonist treatment conditions in the 
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current study as both results stem from different experiments. Thus, further 
chapters in this dissertation will use other measures of anxiety to corroborate the 
anxiolytic impact of EC and the specific role of FGF-2 in such effects both acutely 
and chronically.  Moreover, we will also evaluate how individual differences in 
anxiety like behavior relate to hippocampal FGF-2 expression and how this 













EC significantly increased FGF-2 expression in the Dentate Gyrus, [T(21)=4.53, p<0.001], CA3 
region, [T(21)=3.5, p<0.01], and CA1 region, [T(21)=5.6, p<0.0001] whereas no significant effects 
where observed in the CA2 region [T(21)=0.23, p=0.82](n=11-12 per group). 
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A) EC training decreases anxiety-like behavior as shown by a decrease in the latency to feed on 
the novelty suppressed feeding test [T(20)=-2.2, p<0.05]. B) These results were specific to the 













A) EC significantly increases cell proliferation in the Dentate Gyrus as shown by an increase in 
the number of Ki67 labeled cells, [T(15)=2.8, p<0.05].  B) EC also increase survival of newly born 
cells in the dentate gyrus as measured by the number of Brd-U labeled cells [T(15)=3.7, p<0.01]. 
(n=8-9  per group). 
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Figure 2-4: FGF receptor antagonism blocks the effects of Environmental Complexity on 







A) EC results in a significant increase in cell proliferation as shown by an increase in the number 
of Ki67 cells [F(1,8)=5.8, p<0.05], however such effects are lost when EC animals are treated 
chronically with an FGF receptor antagonist [F(1,8)=2.2, p=0.20].  B) Similarly, EC's significant 
effects on increasing new cell survival [F(1,8)=10.6, p<.01] where lost with concurrent treatment of 

















Under basal conditions EC animals respond with a significant decrease in anxiety as shown by a 
decrease in the latency to feed [T(20)=-2.2, p<0.05].  On the other hand, when EC animals are 
treated with an FGF antagonist this significant change in anxiety behavior in lost.  Thus, FGF 
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Chapter 3  
 
Hippocampal Fibroblast Growth Factor System 
Modulates Anxiety-like Behavior Acutely: Effects in 





The fibroblast growth factor (FGF) system, along with other growth factors, has 
been implicated in the pathophysiology of psychiatric illness including 
depression.  Moreover, growth factors such as BDNF have been shown to 
reduce depressive-like behavior, while increasing anxiety behavior.  To further 
characterize the role of the FGF system on anxiety, we tested the effects of FGF-
2 in the High Responder (HR), Low Responder (LR) model of individual 
differences in emotionality, were HR animals show decreased anxiety like 
behavior compared to LR in the Elevated Plus-Maze (EPM). We also tested the 
effects of FGF receptor blockade on anxiety via hippocampal microinjections of 
the PD173074 FGF receptor antagonist.  Acute administration of FGF-2 resulted 
in an overall increase in anxiety, and this was differentially observed in HR 
animals as demonstrated by their decreased time spent in the open arm of the 
EPM.  Furthermore, the role of the hippocampal FGF system in enhancing 
anxiety acutely was supported by the anxiolytic effect of the FGF receptor 
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antagonist PD173074 upon direct microinjection in the hippocampus.  The 
anxiolytic effect of FGF receptor blockade was evidenced by increased time 
spent in the center of the Open Field as well as time spent in the open arms of 
the EPM.  Taken together our results demonstrate a complex role of 





FGF-2 is a member of the FGF gene family composed of 24 proteins that have 
multiple functions including angiogenesis and nervous system development 
(Eckenstein et al., 1991).  In the adult, FGF-2 shows prominent expression in 
astrocytes throughout the brain, whereas neuronal expression is almost 
exclusive to the hippocampus (Woodward et al., 1992).  Several isoforms of FGF 
2 ranging from 18 kD to 34 kD have been identified (Nugent and Iozzo, 2000).   
FGF-2 exerts its functions by interacting with four receptor types with varying 
affinity depending on ligand and receptor isoforms (Ornitz, 2000, Reuss and von 
Bohlen und Halbach, 2003).  These receptors are trans-membrane glycoproteins 
containing three Ig-like loops (I-II-III) in the extracellular domain and a split 
tyrosine kinase domain.  Three of the FGF receptors, FGFR1, FGFR2 and 
FGFR3, are expressed in the brain (Eckenstein, 1994), while FGFR1 is most 
abundantly expressed in the hippocampus (Belluardo et al., 1997).  
  
A current hypothesis proposes that a deficiency in growth factors is a key 
contributor to the pathophysiology of mood disorders (Duman and Monteggia, 
2006).  While previous work had focused on BDNF, findings by our research 
group first demonstrated a down-regulation of several members of the FGF 
family, including FGF-2 in postmortem brains of subjects that had suffered from 
major depression (Evans et al., 2004).  We have recently extended these human 
findings to animals and demonstrated a down regulation of hippocampal FGF-2 
in a social stress model of depression in the rat (Turner et al., 2008a).   
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While our group has established the potential role of the FGF system in mood 
disorders, most studies on antidepressants have mostly focused on the role of 
BDNF as a mediator of the long-term effects of these drugs on behavior and 
mood (Duman, 1998, Shirayama et al., 2002, Duman, 2004). However, reports 
have also shown that antidepressant treatment increases FGF-2 expression in 
rat hippocampus (Mallei et al., 2002).  These findings suggest that decreased 
levels of FGF-2 may be involved in the pathophysiology or the course of severe 
depression, and that antidepressants may exert their effects by increasing FGF-
2. Furthermore, while BDNF has been shown to display antidepressant effects in 
animal models of depression, (Shirayama et al., 2002) recent findings from our 
laboratory show that FGF-2 also exerts antidepressant effects (Turner et al., 
2008b). 
 
While this body of evidence points to a role of endogenous FGF-2 in exerting 
antidepressant effects, it also raises an interesting dilemma:  stimuli that lead to 
increased anxiety such as stress, have also been linked to enhanced FGF-2 
expression.  For example increased hippocampal FGF-2 has been shown in 
response to acute restraint stress (Molteni et al., 2001, Fumagalli et al., 2005). 
Furthermore, exposure to acute predator stress has resulted in increased levels 
of FGF-2 expression as measured by microarray in PVG hooded rats, which 
display high anxiety behavior (Wang et al., 2003). Moreover, manipulations of 
corticosterone levels have been shown to modulate FGF-2 expression in the 
hippocampus.  Specifically, adrenalectomy resulted in decreased FGF-2 
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expression, whereas corticosterone replacement rescued these effects 
suggesting that corticosterone modulates levels of FGF-2 expression in the 
hippocampus (Molteni et al., 2001).  Furthermore, exogenous corticosterone has 
been shown to directly impact and increase FGF-2 expression in the 
hippocampus while corticosterone synthesis inhibition blocked the stress-induced 
FGF-2 response (Frank et al., 2007). 
 
There are some lines of evidence that can help reconcile these two disparate 
findings regarding the relationship between FGF-2 and emotional responses. 
Given the antidepressant effects of FGF-2 noted above, and the increase in 
FGF-2 triggered by classical antidepressant drugs, it is important to note that 
several antidepressants have been known to increase anxiety during the early 
phases of treatment (Bagdy et al., 2001).  Interestingly, while BDNF over-
expressing mice display an antidepressant-like behavioral phenotype, they also 
exhibit an increase in anxiety behavior (Govindarajan et al., 2006).   This 
supports the notion that growth factors may exert antidepressant properties but 
their effects may also extend to enhance anxiety behavior, at least in the short 
term, in a fashion similar to that of antidepressants.  While the antidepressant 
role of FGF-2 has been described (Turner et al., 2008b), its role in modulating 
anxiety has yet to be explored. Thus, the current experiments were aimed at 
exploring the potential impact of hippocampal FGF-2 on anxiety behavior after 




While the current studies will explore the potential effects of acute FGF-2 on 
anxiety behavior it is important to also evaluate the chronic effects of FGF-2.  
This is important, as acute treatments with selective serotonin reuptake inhibitors 
(SSRIs) and other antidepressants are known to be anxiogenic (Bagdy et al., 
2001), whereas their antidepressants effects extend to reduce anxiety after 
chronic treatment (Dulawa et al., 2004).  Thus, it is possible that treatments with 
FGF-2 may have a similar response as antidepressants on measures of anxiety, 
where acute administration could serve anxiogenic effects whereas chronically 
they may serve to reduce anxiety.   
 
However, in light of this potential discrepancy, in this chapter we first focus on 
investigating the acute effects of FGF system manipulations on anxiety.  
Specifically we first tested the impact of an FGF antagonist on anxiety acutely as 
previous results from Chapter 2 suggested that FGF receptor activation is 
required for environmental complexity to decrease anxiety.  Finally, we followed 
these studies with acute treatments with FGF-2 in order to test whether FGF-2 
specifically, altered anxiety given that in our previous chapter hippocampal FGF-
2 seemed to correlate with decrease anxiety as a result of EC. Thus, our current 








Male Sprague-Dawley rats (375-450g) were selectively bred based on their 
locomotor response to novelty at our in-house colony at the Molecular and 
Behavioral Neuroscience Institute (MBNI).  Adult rats (85-90 day old) were 
housed two animals per cage after locomotor screening (were an HR animal was 
always paired with an LR animal under a 12 hr light/dark cycle with food and 
water available ad libitum.  Animals were allowed to acclimate to the housing 
conditions for 7 days prior to any experiments.  All animals were treated in 
accordance with the National Institutes of Health guidelines on laboratory animal 
use and care and in accordance with the guidelines of the animal ethics 




For each generation of breeding, naïve animals were handled for three 
consecutive days prior to testing to familiarize them with the investigator, then 
screened for locomotor response to a novel environment by placing them in a 
standard size (43×21.5×24.5) clear acrylic cage in a different room from where 
the animals had been housed.  Locomotor activity was monitored every 
5 minutes for 1 hour by two panels of photocells connected to a computer. The 
first panel of three photocells was placed at ground level to record horizontal 
locomotion, with the second panel of five photocells located near the top of the 
cage to determine rearing behavior. The locomotion testing rig and motion 
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recording software were created in-house at the University of Michigan. 
Locomotion activity was tested between 9.00 and 11.30 am.  Final locomotion 
scores were determined by summing horizontal and rearing activities. 
 
Peripheral FGF-2 Injections 
 
Rats were administered FGF2 (1ng/g, 10ng/g, or 20ng/g i.p.) or vehicle (0.1M 
PBS with .1% BSA). Animals were tested for anxiety-like behavior 8 hrs after 
injection on the Elevated Plus Maze (EPM) test, as it has been shown previously 
that brain levels of FGF2 peak 8 hours post peripheral injections of bFGF 
(Wagner et al.1999).  
 
 
Surgery and Microinjections 
 
Rats were anesthetized using isoflurane before surgery and bilateral guide 
cannulae (22-gauge, Plastics One Inc., VA. USA) were implanted into the dorsal 
hippocampus (coordinates from bregma: AP:-5.0 ML:+3.5 DV:-2.1) using a 
stereotaxic apparatus. The guide cannulae were anchored to the skull and fitted 
with an obdurator. Seven days after surgery, the obdurators were removed and 
28-gauge injector cannulae were inserted extending 1.5mm below the tip of the 
guides. The cannulae were connected by PE-20 tubing to a Hamilton syringe 
mounted on a syringe pump (Harvard Apparatus, MA. USA).  LR rats were 
microinjected with PD173074 (Pfizer) at 1nM, 10nM and 100nM, doses dissolved 
in artificial extracellular fluid (aECF). Total volume of 1ul was infused at a rate of 
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1.0µl/min, and injectors were left in place for an additional 2 min to allow diffusion 
of the drug.  Animals were then subjected to behavioral testing within 5 minutes 
of injection.  Rats were killed by decapitation and the brains were snap frozen in 
isopentane after behavioral testing. The brains were sliced and cresyl violet 
staining was performed to verify the placement of the microinjection cannulae.  
 
Elevated Plus Maze (EPM) 
 
Rats were tested 5 min after the microinjection or 8 hours post peripheral 
injections on the elevated plus maze, which was constructed of black Plexiglas, 
with four elevated arms (70 cm from the floor, 45 cm long, and 12 cm wide).  The 
arms were arranged in a cross, with two opposite arms enclosed by 45-cm-high 
walls, and the other two arms open. At the intersection of the open and closed 
arms, there was a central 12×12 cm square platform giving access to all arms.  
The test room was dimly lit (approximately 40 lux), and behavior was monitored 
using a computerized videotracking system (Noldus Ethovision, Leesburg, VA).  
At the beginning of the 5 minutes test, each rat was placed in the central square 
facing a closed arm. The computerized tracking system recorded the latency to 
first enter the open arm, the amount of time spent in the open arm, closed arm, 
or center square over the course of the 5 minutes test.  Behavior testing was 





The open field maze was a 150×150×50 cm3 white Plexiglas box with the floor 
marked into 16 equals 37.5 cm2 squares.  Testing was conducted under dim light 
(40 lux) and recorded using a computerized videotracking system (Noldus 
Ethovision, Leesburg, VA).  The experiment was started by placing the rat into 
one corner of the open field. The computerized tracking system recorded the 
amount of time spent in the center, periphery, or corner of the test apparatus 
over the course of the 5 minutes test. Behavior testing was performed between 




Behavioral studies were analyzed by T-test  or Analysis of Variance.  Data are 




Hippocampal FGF receptor blockade decreases Anxiety-like Behavior 
 
To begin examining the role of the FGF system on anxiety we first aimed to 
determine the effects of acute FGF receptor blockade on anxiety-like behavior.  
For these experiments we targeted the dorsal hippocampus due to its high 
density of neuronal FGF receptor expression and given that the hippocampus 
has previously been implicated in modulating individual differences in anxiety 
behavior as seen in HR and LR.  As seen in Figure 3-1., hippocampal 
microinjections with the FGF receptor antagonist PD173074 resulted in an overall 
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decrease in anxiety behavior on the EPM as shown by an increase in the percent 
time spent in the open arm [t(13)= 3.1, p<0.01] and a decrease in the latency to 
enter the open arm, [t(13)= -.2.5, p<0.05].  Moreover, we also evaluated the 
effects of the FGF receptor antagonist PD173074 on the Open Field test, where 
we also observed a decrease in anxiety as seen by an increase in the 
percentage of time spent in the center [t(10)=3.5, p<0.01] and a decrease time 
spent in the corners [t(10)= -2.3, p<0.05].  Finally, we also evaluated the extent of 
the effects of the FGF receptor antagonist on the EPM to determine whether 
such effects varied with doses. As seen in Figure 3-2., we found that the effects 
of the PD173074 compound on decreasing anxiety are partially dose dependent 
with anxiolytic effects progressively increasing with increasing doses.  
Specifically, we saw that the middle dose at 10nM and highest dose at 100nM 
concentration were the most effective at increasing the percentage of time spent 
in the open arm compared to vehicle controls, (p<0.01). 
 
Peripheral FGF-2 Increases Anxiety-like Behavior 
 
Given that we saw an anxiolytic effect in response to hippocampal FGF receptor 
blockade we wanted to distinguish whether acute FGF-2 specifically mediates 
the FGF system’s impact on anxiety behavior in the EPM.  To this end we 
administered FGF-2 or vehicle peripherally (i.p) in HR and LR to test whether this 
impact was also dependent on individual differences in anxiety-like behavior.  As 
seen in Figure 3-3., acute treatment with FGF-2 results in an overall significant 
increase in anxiety-like behavior.  Overall FGF-2 treated animals show an 
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increase in the latency to enter the open arms [F(3,33)=4.7, p<0.05].  Moreover the 
anxiogenic effects of FGF-2 were also evident as shown by an overall decrease 
in the percent time spent in the open arms [F(3,33)=5.6, p<0.05] and a decrease in 
the percent of open arm entries [F(3,33)=5.2, p<0.05].  We also saw a significant 
interaction effect of treatment and phenotype where Fisher’s PLSD post hoc tests 
revealed that FGF-2 treated HR animals showed a differential decrease in the 
percent time spent in the open arms relative to vehicle treated control HRs 
(p<.01).  
 
Following our initial results where FGF-2 resulted in enhancement of anxiety-like 
behavior an acute dose response study was performed to determine whether the 
anxiogenic effects of FGF-2 observed on the EPM where dose dependent.   For 
these purposes FGF-2 was injected at 1ng/g, 10ng/g and 20ng/g to HR and LR 
animals eight hours prior to testing on the EPM.  As seen in Figure 3-4., we saw 
an overall effect of phenotype [F(7,57)=4.7, p<0.001] where HR animals show less 
anxiety behavior relative to LRs as seen by an overall higher percentage of time 
spent in the open arms of the EPM. Furthermore, there was an interaction effect 
of treatment where Fisher’s PLSD post hoc tests revealed that FGF-2 results in a 
differential increase in anxiety at the 10ng/g dose relative to the vehicle treated 
animals as shown by a decrease in the percentage of time spent in the open arm 
(p<0.05).  These results show that FGF-2 shows a dynamic U-shaped curve 
effect on anxiety-like behavior on the EPM as no differences in anxiety were 
observed at the lower (1ng/g) and higher (20ng/g) doses.  Moreover, as seen in 
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our initial experiments there was an interaction effect of phenotype and treatment 
[F(7,57)=5.1, p<0.01].  Fisher’s PLSD post hoc tests revealed that FGF-2 at the 
10ng/g dose differentially increases anxiety in HRs relative to the vehicle treated 





The present study demonstrates for the first time the direct role of the 
hippocampal FGF system in modulating anxiety behavior.  Our results show that 
acute exogenous treatment with FGF-2 increases overall anxiety like behavior, 
with anxiogenic effects being stronger in Selectively Bred HR animals, which 
normally display lower anxiety relative to Selectively Bred high anxiety LRs 
(Stead et al., 2006).  Moreover, effects of FGF-2 on anxiety displayed a U-
shaped curve as shown by the anxiogenic effects of the middle dose and lack of 
effects from lower and higher doses.  Finally, in support of the modulatory role of 
the endogenous FGF system on anxiety-like behavior, intra-hippocampal 
blockade of FGF receptor decreased anxiety in the EPM and Open Field Test.  
Taken together the results presented above implicate the hippocampal FGF 
system as key a modulator of anxiety behavior and suggest that acutely FGF-2 
increases anxiety like behavior.  
 
Our findings showed acute peripheral treatments with FGF-2 resulting in an 
overall increase in anxiety in the EPM as shown by an increase in the latency to 
 
 88 
enter the open arm, a decrease in the percent time spent in the open arms and 
percent of open arm entries.  Furthermore, our results show that FGF-2 
differentially enhanced HR’s anxiety behavior as shown by a selective decrease 
in the percent of time spent in the open arms.  Although our results failed to show 
significant differential effects in the additional measures of anxiety such as the 
latency to enter open arm and open arm entries, our results due point to a trend 
for the anxiogenic effects of FGF-2 to be differential in HR’s.  For example, while 
our results do point to an overall effect of FGF-2 in increasing anxiety, they show 
that HRs display a three-fold change in the latency to enter the open arm 
compared to a two-fold change in LRs.  Furthermore, the trend on the differential 
impact of FGF-2 treatment in HRs is even more evident in the percent of open 
arm entries as HRs show a 37% percent decrease compared to LRs, which show 
a 17% change.  Taken together these results suggest that FGF-2 is more 
effective at increasing anxiety in animals that naturally display lower anxiety such 
as the HRs.  On the other hand its anxiogenic impact on LR animals, which 
naturally display high anxiety is more moderate.  These differences in response 
to FGF-2 could be related to a floor effect of the LR phenotype on anxiety or to 
existing neurobiological differences between HRs and LRs related to levels of 
FGF-2 expression in the hippocampus.  
 
While our results support the notion that FGF-2 modulates anxiety-like behavior, 
our findings with the use of the FGF receptor antagonist specifically point to the 
hippocampal FGF system as a key player in maintaining an endogenous tone of 
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anxiety.  As presented above, intrahippocampal treatment with an FGF receptor 
antagonist resulted in decrease anxiety as shown by a decrease in the latency to 
enter the open arms and an increase in the percent of time spent in the open 
arms.  Furthermore, the anxiolytic effects of FGF receptor blockade were also 
observed in the Open Field test as shown by a decrease in the percent of time 
spent in corners and an increase in the percent of time spent in the center.  
Finally, our results show that FGF blockade effects on reducing anxiety are 
dependent on dose.  Doses of 10nM and 100nM, which have previously shown 
to block FGF-2 mediated effects on proliferation (Bansal et al., 2003), showed 
significant differences on decreasing anxiety, while a lower dose of 1nM was not 
effective at altering anxiety behavior. These results confirm that hippocampal 
FGF receptor activity is required for maintaining an endogenous tone on anxiety 
behavior. 
 
The present study presents two major findings for the first time; acute treatment 
with FGF-2 increases anxiety-like behavior and hippocampal FGF receptor 
blockade reduces anxiety, thus directly implicating a novel function for this 
growth factor in modulating emotional behavior.  Although these findings 
represent a new function for hippocampal FGF-2 by regulating emotionality, 
previous reports also support the role of growth factors in being active 
modulators of emotional behavior.  Specifically, transgenic mice overexpressing 
BDNF show higher anxiety behavior relative to wildtype (Govindarajan et al., 
2006). However, these animals overexpressed BDNF in the entire forebrain while 
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its functional relevance to anxiety was regarded as being modulated by the 
amygdala. 
 
Conversely, our results point to the hippocampus as being an active modulator of 
FGF mediated anxiety behavior.  Although most reports point to the amygdala as 
being the key structure responsible for modulating anxiety, several reports do 
support the role of the hippocampus in anxiety behavior.  It has been suggested 
that the hippocampal lesions produce anxiolytic effects through behavioral 
disinhibition (Bannerman et al., 2002, Bannerman et al., 2004). These reports 
include anxiolytic effects on tests of anxiety such as the novelty suppressed 
feeding test, and the Elevated Plus maze (Bannerman et al., 2002).  Thus our 
results support the notion that the hippocampus is an active player in the 
modulation of anxiety and further elaborate on one specific molecule, FGF-2, as 
being a key modulator.  
 
Finally while FGF-2 acutely was shown to be anxiogenic, it is important to 
consider that opposite effects may occur in response to chronic treatment.  As 
previously mentioned acute treatment with SSRI antidepressants increases 
anxiety (Bagdy et al., 2001) whereas chronically they are anxiolytic (Dulawa et 
al., 2004).  Therefore, it is plausible that FGF-2 may have similar effects on 
anxiety given that FGF-2 increases in response to chronic antidepressant 
treatment (Mallei et al., 2002). Moreover, FGF-2 itself has previously been shown 
to have antidepressant-like effects (Turner et al., 2008b).  Thus, FGF-2 seems to 
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show a therapeutic profile equal to SSRI antidepressants, where it reduces 
depressive like behavior, but not without first increasing anxiety acutely.  This 
leads us to suspect that FGF-2 may have anxiolytic effects after chronic 
treatment.  In support of this notion are the findings from our previous chapter 
showing EC increasing FGF-2, while requiring FGF receptor activation for its 
anxiolytic effects. Consequently, the following chapter will specifically test 
whether chronic FGF-2 reduces anxiety behavior.  Moreover, we will further test 
the extent to which the HR and LR anxiety phenotypes are important factors in 
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A) FGF receptor antagonist PD173074  decreases anxiety on the EPM as shown by an increase 
in the percent of time spent in the open arm [T(13)= 3.1, p<0.01 and B) a decrease in the latency 











C) FGF receptor antagonist PD173074 decreases anxiety on the Open Field as shown by an 
increase in the percentage of time spent in the center [T(10)=3.5, p<0.01] and a decrease time 









FGF receptor blockade reduces anxiety. FGF receptor antagonist PD173074 decreases anxiety 
in a dose dependent manner were the middle dose at 10nM and the highest doses at 100nM 
concentration were both equally effective at increasing the percentage of time spent in the open 










A) FGF-2 significantly increases anxiety-like behavior as shown by an overall increase in the 
latency to enter the open arms ) [F(3,33)=4.7, p<0.05]. B) FGF-2 anxiogenic effects are also 
observed as an overall decrease in the percent of open arm entries [F(3,33)=5.2, p<0.05]. n=9-11 
per group)  
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C) FGF-2 resulted in an overall decrease in the percent of time spent in the open arms 
[F(3,33)=5.6, p<0.05]. A significant interaction of phenotype and treatment was also observed as 
FGF-2 resulted in a differential decrease in the percentage of time spent in the open arms in HR 










FGF-2 shows a dynamic U-shaped curve effect on anxiety-like behavior on the EPM.  FGF-2 
differentially increases anxiety at the 10ng/g dose relative to the vehicle treated animals as shown 
by a decrease in the percentage of time spent in the open arm (p<0.05) as no effects were seen 
at higher or lower doses. HR animals show less anxiety behavior relative LRs as seen by an 
overall higher percentage of time spent in the open arms of the EPM [F(1,57)=4.7, p<0.001]. There 
was also an interaction effect of phenotype and treatment [F(7,57)=5.1, p<0.01], where Fisher’s 
PLSD post show FGF-2 at the 10ng/g dose differentially increasing anxiety in HRs relative to the 
vehicle treated HRs as shown by a decrease in the percentage of time spent in the open arms 
(p<0.0001) (n=7-9 per group) 
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Chapter 4  
 




Human postmortem studies have demonstrated that FGF-2 expression is 
decreased in the brain of severely depressed individuals. It remained unclear, 
however, whether this is a consequence of the illness or whether FGF-2 plays a 
primary role in the control of mood and emotions.  In this series of studies, we 
first asked whether endogenous FGF-2 expression correlates with spontaneous 
anxiety, a trait associated with vulnerability to severe mood disorders in humans. 
This was tested in two genetically distinct groups of rats selectively bred to differ 
dramatically in their response to novelty and to anxiety-provoking conditions 
(HRs= Low Anxiety/High Response to Novelty vs. LRs= High Anxiety/Low 
Response to Novelty). We demonstrated that the Low-Anxiety HRs have 
significantly elevated levels of hippocampal FGF2 mRNA relative to the High-
Anxious LRs, and that there exists a highly significant inverse correlation 
between FGF-2 levels and anxiety behavior. We then demonstrated that FGF-2 
expression is modulatable by environmental factors that alter anxiety, thus 
environmental complexity (EC) reduced anxiety behavior and induced FGF-2 
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expression in hippocampus, particularly in the High Anxious LRs.  Finally, we 
directly tested the role of FGF-2 as an anxiolytic and show that a 3-week 
treatment regimen of peripherally administered FGF-2 was highly effective at 
blunting anxiety behavior, specifically in the high anxiety LRs. This treatmen 
effect was accompanied by an increase in survival of hippocampal adult stem 
cells, both neurons and astrocytes, again specifically in the LRs.  Taken together, 
these findings implicate hippocampal FGF-2 as a novel modulator of anxiety 






The molecular factors that impart either vulnerability or resilience to mood and 
anxiety disorders remain elusive in spite of active efforts to elucidate their genetic 
bases. Gene expression profiling in postmortem human brains represents a 
complementary approach that can uncover molecular changes associated with 
these disorders. Expression profiling of the frontal cortex of severely depressed 
individuals revealed that the fibroblast growth factor (FGF) system was the most 
significantly altered family of molecules relative to controls (Evans et al., 2004). 
This work has since been extended to other brain regions, including the 
hippocampus and amygdala and has shown a consistent decrease of FGF2 
mRNA and FGF-R2 mRNA in most brain regions examined (Akil et al., 2008). In 
particular, the decrease in FGF-2 mRNA has been independently documented in 
the hippocampus (Gaughran et al.), supporting the association between FGF 
system dysregulation and mood disorders.  
 
However, it is difficult to distinguish whether the observed differences represent 
predisposing factors to the illness or are secondary to the disease process. We 
therefore undertook a series of studies using animal models to ask whether 
members of the FGF families can indeed modulate affective behavior, and 
whether they may constitute predisposing factors for individual differences in 
emotional reactivity. Here we focused on the role of the FGF system in anxiety-
like behavior, given that anxiety is one of the hallmarks of depression, that there 
is significant co-morbidity between anxiety and major depression and that there 
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is mounting evidence that the two disorders may be closely associated due to a 
common etiology or risk factors as reviewed by, (Gorwood, 2004).  We focused 
on FGF-2 because it is one of the 22 FGF family members that exhibit the most 
consistent changes in major depression, as well as being one of the best studied 
FGF’s in the central nervous system. FGF-2 exerts its function by interacting with 
four receptors (Ornitz, 2000, Reuss and von Bohlen und Halbach, 2003), three of 
the which, FGFR1, FGFR2 and FGFR3, are expressed in the brain (Eckenstein, 
1994), with FGFR1 being most abundantly expressed in the hippocampus 
(Belluardo et al., 1997). This growth factor is critical in the development of the 
mammalian brain (Raballo et al., 2000), is known to modulate hippocampal 
neurogenesis in the developing brain (Wagner et al., 1999) and has been 
implicated in adult neurogenesis (Pieper et al., 2005) (Palmer et al., 1995) 
 
In order to test the possible role of FGF-2 in affective behavior, we relied on an 
animal model in which we used a genetic selection strategy in Sprague-Dawley 
rats to enhance basal differences in novelty-seeking and spontaneous anxiety 
behaviors (Stead et al., 2006). Thus, after several rounds of breeding, the 
selectively bred line of High Responders (HR) exhibits significantly greater 
exploration of a novel environment relative to oubtred Sprague-Dawley rats, 
whereas the selectively bred line of Low Responders (LR) exhibits significantly 
lower exploration than outbred animals, as well as dramatic differences from the 
selectively bred HRs. As importantly, the two groups display consistent and 
profound differences in all tests of spontaneous anxiety, with HR’s exhibiting low 
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and LR’s exhibiting high anxiety behavior.  Beyond these basal differences due 
to genetic background, we also manipulated environmental conditions, by 
enriching the rats’ environment and increasing its complexity (EC) and asked 
whether this manipulation impacted anxiety behavior in the two selectively bred 
lines. This model then tested both the possible genetic differences in FGF-2 and 
the environmental modulation of its expression. Given the results from these 
endogenous studies, we went on to administer exogenous FGF-2 in order to 
directly test its potential role in modulating anxiety behavior in the two groups of 
rats and ascertain the correlates of this treatment on the proliferation and survival 
of adult newborn cells in the hippocampus.  
Materials and Methods 
Animals 
 
Adult male Sprague-Dawley rats were obtained from our in-house breeding 
colony at the Molecular and Behavioral Neuroscience Institute (MBNI) where we 
have maintained the selectively-bred HR-LR lines for over 19 generations. HR-
LR lines were selectively bred based on their differences in exploratory response 
to novelty a characteristic initially used to predict individual differences in drug 
taking behavior (Piazza et al., 1989). We recently published a description of our 
breeding strategy and an initial behavioral characterization of the HR-LR 
differences in anxiety-like behavior (Stead et al., 2006).  We have also shown 
that this behavior is likely genetic as it shows little change when animals are 
cross-fostered to a mother from the opposing line (Clinton et al., 2007).  An 
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additional set of outbred Sprague-Dawley rats obtained from Charles River was 
used to provide an intermediate phenotype and determine the correlation of 
anxiety behavior and FGF-2 expression in the hippocampus.  Adult rats (300g-
400g) around 2 months old were housed two animals per cage (one HR, one LR 
per cage) after locomotor screening under a 12 hr light/dark cycle (lights on at 
6:00 am) with food and water available ad libitum.  Animals were allowed to 
acclimate to the housing conditions for at least 7 days prior to any experiments.  
All animals were treated in accordance with the National Institutes of Health 
guidelines on laboratory animal use and care and in accordance with the 
guidelines set by the university committee on use and care of animals (UCUCA) 




At postnatal day 55-60, adult male rats from our selective breeding colony were 
screened for locomotor response to a novel environment by placing them in a 
standard size (43×21.5×24.5) clear acrylic cage in a different room from where 
the animals had been housed. Locomotor activity was monitored every 5 minutes 
for 1 hour by two panels of photocells connected to a computer. The first panel of 
three photocells was placed at ground level to record horizontal locomotion, with 
the second panel of five photocells located near the top of the cage to determine 
rearing behavior. The locomotion testing rig and motion recording software were 
created in-house at the University of Michigan. Locomotion activity was tested 
between 9:00 and 11:30 am. Final locomotion scores were determined by 
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summing horizontal and rearing activities verifying the differential acivity reposne 
to novelty between selectively bred HRs and LRs. (see appendix 4-3) 
 
Light-dark box (LDB) anxiety test 
 
The LDB apparatus is a 30 × 60 × 30-cm Plexiglas shuttle box with a translucent 
cover.  The floor is composed of stainless steel bars suspended above corncob 
bedding.  Each box is divided into two equal-sized compartments by a wall with a 
12 cm-wide open door.  One compartment is painted white and brightly 
illuminated, and the other is painted black with very dim light.  Time spent in each 
compartment is monitored by rows of five photocells located 2.5 cm above the 
grid floor of each compartment, and total time spent in each compartment is 
recorded with a microprocessor. Animals that spend less time in the illuminated 
compartment and more time in the dark compartment are classified as showing 
greater anxiety behavior.  
 
Elevated Plus Maze (EPM) 
 
The elevated plus maze is constructed of black Plexiglas, with four elevated arms 
(70 cm from the floor, 45 cm long, and 12 cm wide). The arms are arranged in a 
cross, with two opposite arms enclosed by 45-cm-high walls, and the other two 
arms open. At the intersection of the open and closed arms, there is a central 
12×12 cm square platform giving access to all arms. The test room is dimly lit 
(approximately 40 lux), and behavior is monitored using a computerized video 
tracking system (Noldus Ethovision, Leesburg, VA). At the beginning of the 
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5 minutes test, each rat is placed in the central square facing a closed arm. The 
computerized tracking system records the latency to first enter the open arm, the 
amount of time spent in the open arm, closed arm, and center square over the 





To increase the complexity of the environment, rats were housed for 21 days in 3 
× 3 × 3 ft stainless steel cages which contain different toys, obstacle courses, 
and enriching stimuli.  The number of toys is increased over the course of the 3 
weeks of EC. Thus, every day, animals are exposed to novel sensory stimuli and 




The Chronic FGF-2 regimen involved the administration of either FGF-2 (5 ng/g, 
i.p) or vehicle (0.1M PBS with 0.1% BSA) every day for three weeks.  Systemic 
injections with this dose have previously been shown to alter neurogenesis 
(Wagner et al., 1999).  The three-week treatment period is used to match the 
duration of the EC housing period.  Animals are then tested for anxiety measures 




mRNA in situ Hybridization  
 
At the conclusion of each experiment, rats were sacrificed by rapid decapitation, 
and their brains removed, snap frozen in isopentane, and stored at -80 ºC.  
Brains were cryostat sectioned at -20°C at 20µm for the EC studies or 10µm for 
the basal HR-LR studies and sliced in series throughout the hippocampus, 
mounted on Super Frost Plus slides (Fisher Scientific) and stored at -80°C until 
processed. In situ hybridization methodology has been previously described in 
detail elsewhere (Kabbaj et al., 2000). The FGF-2 probe was labeled in a 
reaction mixture consisting of 1µg of linearized plasmid, 1X transcription buffer 
(Epicenter Technologies, Madison, WI), 125 µCi of 35S-labeled-UTP, 125 µCi of 
35S-CTP, 150 µM ATP and GTP, 12.5mM dithiothreitol, 1 µl of RNase inhibitor, 
and 1.5 µl of T3 RNA polymerase. Radioactive signals were quantified using 
computer-assisted optical densitometry software (Scion Image Beta 4.03; Scion 
Corporation, Frederick, MD). Integrated densities were determined by outlining 
the region of interest from both hemispheres. Optical density measurements 
were corrected for background, and the signal threshold defined as the mean 
gray value of background plus 3.5X its standard deviation. Only pixels with gray 
values exceeding the above-defined threshold are included in the analysis.  In 
the present studies, optical density measurements were taken for 4 subregions of 
the hippocampus (hippocampus fields CA1-CA3, and the dentate gyrus) from the 
left and right sides of the brain. Data from multiple sections per animal were 
averaged resulting in a mean integrated optical density value for each animal and 





To assess the effect of FGF-2 on hippocampal new cell survival, rats were 
injected with BrdU (Calbiochem) once daily for two days prior to the start of 
treatment paradigm at a dose of 200mg/kg dissolved in saline.  Twenty-four 
hours post BrdU labeling animals underwent 21 days of FGF-2 treatment before 
being exposed to behavior testing after which they were sacrificed by 
decapitation and brain were snap frozen.  For determining the rate of cell 
proliferation we performed immunohistochemical labeling of Ki-67, which is an 
endogenous marker of ongoing cell proliferation. For BrdU and Ki67 
immunohistochemistry a series of every 8 sections was cut throughout the entire 
extent of the hippocampus at 30µm and slide mounted.  For Ki-67 DAB staining, 
sections were postfixed in 4% paraformaldehyde for 1hr, followed by a 45 minute 
incubation in 10mM Sodium Citrate at 90°C.  Sections were then rinsed with PBS 
and washed in 0.3% peroxide followed by blocking with BSA containing 1% goat 
serum and 0.05% Triton X-100.  Subsequently sections were incubated overnight 
with rabbit polyclonal anti-ki67 (University of Michigan) 1:40000 in BSA.  After 
PBS washes sections were incubated in biotinylated goat anti rabbit secondary 
antibody 1:1000, (Vector labs) followed by avidin/biotin complex (Vectastain Elite 
ABC kit) and subsequent DAB reaction for visualization of signal.  For DAB 
staining of BrdU, sections were postfixed in 4% paraformaldehyde for 1hr, rinsed 
in PBS and washed in 0.3% peroxide.  Sections were then incubated in 50% 
formamide-2X SSC at 65°C for 2 hours followed by two 5 minute rinses in 2X 
SSC.  Slides are then placed for 30 minutes in 2N HCL at 37°C and 10 minutes 
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in 0.1M boric Acid at room temperature, followed by rinsing in PBS and blocked 
with BSA containing 1% goat serum and 0.05% Triton X-100.  Sections were 
incubated overnight at room temperature with rat monoclonal anti-BrdU 
(Accurate) 1:1000 in BSA. After PBS washes sections were then incubated in 
biotinylated goat anti rat (Vector labs) secondary antibody 1:1000 followed by 
Avidin/Biotin complex amplification (Vectastain Elite ABC kit) and subsequent 
DAB reaction for visualization of signal. Cresyl violet staining was performed for 
both immuno-stains and sections are subsequently dehydrated through graded 
alcohols followed by immersion in xylene and then coverslipped with Permount® 
mounting medium.    For Fluorescent triple labeling we used 1:1000 dilution of rat 
anti-BrdU in combination with 1:1000 dilution of mouse monoclonal anti-GFAP 
(Chemicon). For NeuN labeling we use a primary monoclonal mouse anti-NeuN 
antibody tagged with an Alexa 488 fluor (Chemicon).  For fluorescent secondary 





For quantification of DAB stained Ki-67 and BrdU cells, slides were initially coded 
and the code was not broken until counts were analyzed to ensure that a blind 
observer performed all cell counts.  To estimate the total number of cells we 
followed a modified unbiased stereological procedure used by (Malberg and 
Duman, 2003) whereby the total number of cells counted per animal was 
multiplied by the reciprocal of the sampling factor.  BrdU and Ki67 cells were 
 
 111 
counted on a light microscope under 63X objective in the granule cell layer and 
subgranular zone (SGZ) of the hippocampus located at the border of the granule 
cell layer.  Cells were included in SGZ counts if the cell is near the SGZ or 
touching the SGZ and excluded if the cell is more than two cell diameters from 
the SGZ.  In triple labeling experiments at least 30 BrdU cells were examined per 
subject to determine the percentage of BrdU positive cells that co-label with 
NeuN or GFAP using a laser scanning confocal microscope.  Laser scans of 
0.5µm serial Z-section planes were visualized using a 63x objective to determine 
the Neuronal or Glial differentiation of BrdU positive cells.  To obtain an estimate 
of the total number of new neurons and new glial cells in the hippocampus of 
each animal, we used the percent of BrdU+ cells co-labeled with NeuN, GFAP or 




Behavioral studies and anatomical studies were analyzed by ANOVAs followed 
by Fishers PLSD post-hoc comparisons. Baseline HR-LR in situ hybridization 
studies were analyzed by Students t-test. Pearson correlation test was used was 
used to evaluate relationship between hippocampal FGF-2 mRNA expression 
and behavioral anxiety measure. All data are presented as mean +/- standard 






FGF-2 is decreased in the Hippocampus of High Anxious LR animals. 
 
To elucidate the role of FGF-2 in modulating anxiety behavior, we examined 
basal levels of FGF-2 gene expression in the selectively bred HR and LR 
animals, which have been previously shown to display basal differences in 
anxiety behavior.   We specifically began examining the hippocampus as this 
region has been previously shown to be the primary target region modulating 
HR-LR differences in anxiety-like behavior and is a region where FGF-2 shows 
prominent neuronal expression, and exhibits dysregulation in human depressed 
subjects.   As seen in Figure 4-1 A and B, results show that the high anxiety LR 
animals have lower basal levels of FGF-2 expression in the dentate gyrus 
[t(16)=2.58, p<0.05] and CA3 [t(16)=2.12, p<0.05] relative to the less anxious HR 
animals.  No significant differences between HRs and LRs were observed in the 
CA1 or CA2. 
  
In addition to the selectively bred lines, we studied, outbred Sprague-Dawley rats 
that show the full range of distribution of anxiety-like behavior.   We tested them 
on the EPM for the assessment of anxiety behavior, and then measured their 
resting FGF-2 mRNA levels.  We observed a significant positive correlation 
between the levels of FGF-2 expression in the CA2 region of the hippocampus 
and the amount of time spent in the open arm [R ^2= 0.59, p<0.01] Figure 4-1 C, 
suggesting that elevated resting levels of FGF-2 message may be related to low 
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levels of anxiety behavior.  While we did not observe significant differences in 
FGF-2 expression in the CA2 region between HRs and LRs our results in the 
outbred rats parallel an observed tendency for HRs showing higher levels of 
FGF-2 gene expression.  It is possible that significant differences were not 
observed as a result of saturation of exposure during our In situ hybridization 
experiments with HRs and LRs.  This is a result of high density of FGF-2 
expression in the CA2 region, which is greater than anywhere else in the 
hippocampal formation.  
 
Environmental Complexity differentially reduces anxiety like behavior in LR 
animals.  
 
Given that EC has been previously shown to influence emotionality by reducing 
anxiety (Benaroya-Milshtein et al., 2004), we aimed at determining whether this 
manipulation would have differential effects in the HR versus LR animals, given 
their basal differences in anxiety behavior.  This behavioral study was also a 
prelude to assessing the impact of this environmental manipulation on FGF2 
expression in the two lines of rats. To test the effects of EC on anxiety behavior 
in HR and LR animals we used the Light Dark Box (LDB) test and Elevated Plus 
Maze (EPM) test as both of these tests have previously been used to 
characterize the behavioral differences between these phenotypic groups. 
 
As seen in Figure 4-2., there was a significant main effect of EC resulting in an 
overall reduction of anxiety-like behavior in both tests. In the LDB test there was 
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a significant main effect of EC on decreasing anxiety-like behavior, as evidenced 
by an overall increase in the percent time spent in the illuminated compartment 
[F(1,35)=6.02, p<.05]. Interestingly, while HR animals spent an overall higher 
percentage of their time in the Illuminated Compartment relative to LR’s 
[F(1,35)=7.7, p<0.01], this was primarily due to the basal differences (i.e. under 
Control, non-EC conditions) and not the EC condition. This is confirmed by the 
finding of a significant interaction effect between HR/LR phenotype and treatment 
(Control vs. EC) [F(1,35)=6.8, p<0.05].  Post-hoc tests revealed a differential effect 
of EC on LR, with LR EC animals displaying significantly less anxiety behavior 
than LR control animals (p<0.01). Thus, the EC manipulation abolished the 
differences in spontaneous anxiety between HR and LR animals, showing that in 
the Light-Dark test, EC has a selective impact in alleviating the anxiety behavior 
of the High Anxious LRs.  In the EPM, as expected, there was a significant main 
effect of phenotype; whereby HR animals displayed lower anxiety behavior 
compared to LR animals as measured by the percent open arm entries 
[F(1,52)=8.1, p<0.01].  EC resulted in an increase in the percentage of open arm 
entries [F(1,52)=20.0, p<0.0001] indicating the anxiolytic impact of this 
manipulation on both groups in the context to the EPM. 
  
Environmental Complexity differentially increases FGF-2 expression in LR 
animals. 
 
Our previous results indicated that HR animals have higher basal levels of FGF-2 
expression in the hippocampus and display lower anxiety relative to LR animals. 
 
 115 
Given the finding that EC reduced anxiety behavior more consistently in the LR 
animals, we asked whether EC resulted in increased FGF-2 expression in the 
hippocampus, and whether this effect was differential across the two selectively 
bred lines of rats.  
 
Our results in Figure 4-3., show that EC training results in an overall significant 
increase in FGF-2 expression in the dentate gyrus, [F(1,19)=23.3, p<0.001], and 
CA3 region, [F(1,19)=16.7, p=0.001].  Moreover, there was an interaction effect of 
EC housing and phenotypic group on FGF-2 expression in the dentate gyrus, 
[F(1,19)=6.17, p<0.05] and in the CA3 region [F(1,19)=6.4, p<0.05]. Post-hoc 
analysis revealed a differential effect on LR EC animals as compared to LR 
controls within dentate gyrus (p<.0001) and CA3 region (p<0.001). Thus, the high 
anxious LR’s showed a greater impact of EC on both their anxiety behavior and 
FGF2 expression in the hippocampus, leading us to hypothesize that FGF2 plays 
a role in mediating the decrease in anxiety that results from exposure to a 
complex environment.  
 
FGF-2 differentially reduces anxiety-like behavior in LR animals. 
 
Given the results above showing that both genetic endowment and 
environmental conditions modulate hippocampal FGF-2 expression, with higher 
levels being correlated with reduced anxiety behavior, we set out to directly test 
the hypothesis that FGF-2 is a key regulator of anxiety behavior. We therefore 
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administered FGF-2 chronically and asked whether it would alter measures of 
anxiety behavior in both the high anxious LR’s and the low anxious HRs. 
  
As illustrated in Figure 4-4., our results show the expected difference in the 
HR/LR phenotype in the LDB test. Importantly, they reveal an overall anxiolytic 
effect of FGF2 treatment. Thus, HR animals overall spent more time in the 
illuminated compartment of the LDB [F(1,46)=38.5, p<0.0001].   Moreover, FGF-2 
treatment resulted in an overall increase in the percent of time spent in the 
Illuminated Compartment of the LDB, [F(1,46)=5.9, p<0.05].  More importantly, 
there was an interaction effect of treatment with phenotype [F(1,46)=5.6, p<0.05].  
Post-hoc analysis revealed FGF-2 treatment having a significant anxiolytic effect 
in FGF-2 treated LRs relative to vehicle treated LRs (p<0.01), whereas no 
significant effect of FGF2 treatment was observed in the HR rats.  
 
A similar pattern was seen in the EPM. Thus, a significant interaction effect of 
chronic FGF-2 treatment x phenotype was observed on measures of anxiety 
behavior in the EPM, including percent of open arm entries [F (1,46)=7.2, p<0.01] 
and percent of time spent in the open arm [F(1,46)=6.1, p<0.05].  Further post-hoc 
analysis revealed that LR animals differentially benefited from the anxiolytic 
effects of chronic FGF-2 treatment, whereas HR animals did not. Thus, FGF2-
treated LRs showed a significant increase in the percent of open arm entries 
(p<0.01) and in the percent of time spent in open arms (p<0.01) relative to 
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vehicle treated LRs. No significant effects were seen when comparing these 
measures in FGF2-treated versus vehicle-treated HRs.  
 
FGF-2 differentially increases new cell survival in LR animals. 
 
Given that EC is well known for increasing neurogenesis and that it produced a 
significant increase in FGF-2 gene expression in the dentate gyrus, it was 
reasonable to hypothesize that increase in neurogenesis post EC may be 
mediated at least in part by FGF-2.  Indeed, exogenous treatment with FGF-2 
has been shown to increase neurogenesis in the dentate gyrus of the 
hippocampus (Wagner et al., 1999, Pieper et al., 2005). Our specific question 
was whether the treatment protocol that we used, chronic peripheral FGF-2 
administration, would alter hippocampal neurogenesis and if it would do so in a 
manner that correlates with the alterations in anxiety behavior—i.e. more 
markedly in the LR rats that are more responsive to the treatment.  
 
As shown in Figure 4-5., HR and LR animals show a non-significant tendency to 
exhibit basal differences in number of BrdU labeled cells (2739 +/- 295 in HR and 
2061 +/-127 in LR) (p=.08).  Chronic treatment with FGF-2 results in a significant 
overall increase in new cell survival in the Dentate Gyrus as shown by an 
increase in the number of Brd-U labeled cells [F(1,16)=18.5, p<0.001].  
Interestingly, chronic administration of FGF-2 produced little change in the total 
number of BrdU cells in HR’s (3270 +/- 306, an 18% increase). By contrast FGF-
2 produced a substantial increase in the total number of BrdU labeled cells in the 
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LR rats (up to 3802 +/- 286) representing a 46% increase. Thus, there was a 
significant interaction of treatment x phenotype  [F(1,16)=5.2, p<0.05].  
 
It is noteworthy that these results where independent of an increase in cell 
proliferation, as we observed no differences between HR and LR in proliferation 
as chronic FGF-2 failed to increase the number of Ki67 labeled cells [F(1,16)=1.1 
p>0.05]. Thus, it appears that HR and LR lines exhibit a tendency towards a 
basal differences in the survival of adult born cells, with the more anxiety prone 
LR’s showing lower rates of survival.   Thus, FGF-2 treatment increases cell 
survival only in the LR animals, in conjunction with their more consistent 
decrease in anxiety behavior.  
 
FGF-2 differentially alters differentiation of adult stem cells in the 
hippocampus of LR animals.  
 
Given the differential increase in cell survival in LRs in response to FGF-2, we 
evaluated the pattern of differentiation of the surviving BrdU labeled cells by 
obtaining an estimate of the total number of neurons and astrocytes generated in 
the hippocampal dentate gyrus as a function of treatment with FGF-2.  
 
Statistical analysis of the data summarized in Table 4-1 shows several main 
effects as well as interaction between HR/LR phenotype and the impact of FGF-2 
treatment on the various stem cell populations. Beyond the tendency for the 
basal differences in total number of BrdU labeled cells described above, HR and 
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LR animals exhibit basal differences in the proportions of cells where BrdU is co-
labeled with NeuN, GFAP or neither (Figure 4-6 A &C).  In particular, relative to 
LRs, HRs show a higher number of new astrocytes generated in the dentate 
gyrus across both vehicle and FGF-2 conditions [F(1,16)=27.1, p<0.0001] and this 
is particularly due to the basal difference in newly born astrocytes (235 + 25  in 
HR vs. 62 + 4 in LR) as shown by post-hoc analysis (p<0.0001) . 
FGF-2 treatment results in an overall increase in the number of new astrocytes 
[F(1,16)=33.1, p<0.0001] and new neurons [F(1,16)=20.2, p<0.001], but the impact is 
different as a function of the HR/LR phenotype. Thus, there were significant 
interaction effects in the number of newly generated neurons [F(1,16)=9.7, p<0.01], 
astrocytes  [F(1,16)=9.6, p<0.01], as well as on undifferentiated cells [F(1,16)=9.5, 
p<.01]. 
 
 As noted above, in the HR animals, chronic administration of FGF-2 produced 
little change in the total number of BrdU+ cells, and Table 4-1., and Figure 4-
6B., show that this held true especially for neurons (13% increase) with a slightly 
greater increase in astrocytes (23%). Interestingly, the small population of BrdU 
labeled cells that was co-labeled with neither marker increased the most post 
FGF-2 (52%; p<0.01) in the HR population.  Such differential increase resulted in 
a disruption of the basal differences between HRs and LRs as under vehicle 





By contrast, in the LR animals, FGF-2 produce a substantial increase in BrdU 
labeled cells, and Table 4-1., and Figure 4-6B., show that this represented a 
doubling of neurons (201% increase over basal; p<0.0001), and a remarkable 
four-fold increase in astrocytes (398% over basal; p<0.0001). The population of 
BrdU labeled cells that was co-labeled with neither marker decreased slightly 
(12%) in LRs. Thus, as depicted in Figure 4-6D, the relative proportions of 
neurons, astrocytes and “neither” was altered by FGF-2 particularly in the LRs, 
with what appears to be a relative proportional increase in astrocytes at the 
expense of uncommitted cells. 
Discussion 
The present study establishes for the first time a role for hippocampal FGF-2 in 
modulating anxiety behavior, and suggests a mechanism for this role via the 
modulation of hippocampal neurogenesis. Our findings are as follows: a) 
selectively bred HR animals, which naturally show lower anxiety-like behavior 
compared to selectively bred LR’s, exhibit higher basal levels of hippocampal 
FGF-2 relative to their LR counterparts. Moreover, in an outbred population, 
higher levels of FGF-2 mRNA predict lower anxiety behavior; b) Exposure to an 
environmental manipulation which increases complexity of the physical 
surrounds of an animal, decreases anxiety behavior and leads to increased 
expression of FGF-2 mRNA. The impact of EC on FGF-2 hippocampal 
expression was seen selectively in the more anxious LR animals, who also 
exhibited a more consistent decrease in anxiety behavior post EC as manifested 
in both the EPM and the LDB; c) chronic administration of exogenous FGF-2 
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decreases anxiety behavior and this is seen only in selectively bred LR’s ; d) 
chronic administration of exogenous FGF-2 increases new cell survival in the 
hippocampus without altering proliferation. This is associated with in an overall 
increase in neurogenesis and glial genesis.  Once again, this effect is seen 
primarily in the LR animals. These results strongly implicate hippocampal FGF-2 
as a modulator of anxiety behavior. Moreover, they show that this modulation can 
take place as a result of a genetic predisposition (HR express more FGF-2 
basally than do LR’s) but that environmental factors, specifically an enriched 
environment, can also induce it, essentially compensating for the genetic 
vulnerability in the more anxiety-prone animals. Finally, this body of work 
suggests that treatment with exogenous FGF-2 or its analogues, or more broadly 
altering the FGF system, may benefit individuals prone to high anxiety. 
 
While FGF2 had not been directly implicated in the control of anxiety, several 
strands of evidence give this view face validity. First, as, indicated above, we and 
others have found that several FGF family members including FGF-2 are 
decreased in the brains of post mortem subjects suffering from major depression 
(Evans et al., 2004),(Gaughran et al., 2006, Akil et al., 2008). Moreover, recent 
animal studies from our group and others support its relevance to depression, as 
FGF-2 is decreased in social defeat, an animal model of depression (Turner et 
al., 2006) and both FGF-2 and related molecules function as antidepressants in 
the Porsolt Swim Test (Turner et al., 2008b). Moreover, chronic classical 
antidepressant drugs have been shown to increase FGF-2 expression (Mallei et 
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al., 2002) and to enhance neurogenesis (Malberg et al., 2000). Thus, this body of 
work is consonant with the current hypothesis that a deficiency in growth factors 
represents a vulnerability factor for mood disorders (Duman and Monteggia, 
2006) and that the induction of growth factors is critical to the effectiveness of 
antidepressant drugs (Warner-Schmidt and Duman, 2007), along with the 
possibility that neurogenesis plays a critical role in antidepressant action 
(Santarelli et al., 2003). Taken together, these findings suggest that decreased 
levels of FGF-2 may be involved in the pathophysiology of depression, and that 
antidepressants may exert their neurogenic effects by increasing FGF-2. 
However, in spite of the close co-morbidity between anxiety disorders and major 
depresive disorders, much less has been done to establish the role of FGF-2 in 
modulating anxiety. More importantly, the findings here suggest that the impact 
of FGF-2 is not only seen under pathological conditions but in the context of 
natural variation in anxiety-like behavior and that it is modulated by relatively mild 
environmental changes (e.g increasing complexity).  
 
The differential impact of Environmental Complexity on FGF-2 and anxiety in LRs 
suggest that some experiences may only benefit certain individuals that have a 
high genetic propensity for anxiety like that observed in the selectively bred LRs 
(Stead et al., 2006). Given the evidence showing FGF-2 decreasing anxiety, it is 
possible that HRs did not show less anxiety in the LDB given the lack of 
beneficial increase in FGF-2 in response to EC.  This could potentially be related 
to a ceiling effect that may have precluded the HR’s increase in hippocampal 
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FGF-2. Although, no differential impact on anxiety in LRs was observed on the 
EPM in response to EC, our results do point to LRs being favored.  Normally, 
LRs show 25% percent open arm entries whereas in response to EC this number 
increases to 47%, representing almost a two-fold decrease in anxiety.  On the 
other hand, HRs low anxiety performance went from 41% to 55%, thus 
resembling a more modest change in anxiety behavior which could alternatively 
be explained by increased expression of BDNF or VEGF in response to EC 
(Young et al., 1999) (Cao et al., 2004).  
 
In support of the role of FGF-2 as a modulator of anxiety, our results indicate that 
chronic exogenous FGF-2 treatment is sufficient for reducing anxiety in LRs.  
This novel role for FGF-2 is supported by anxiolitic treatments increasing FGF-2 
expression in the hippocampus (Gomez-Pinilla et al., 2000, Mallei et al., 2002) 
and by our findings showing EC increasing FGF-2 expression and reducing 
anxiety in LRs.  They also expand on the potential role of endogenous FGF-2 in 
modulating experience dependent anxiety behavior.  In support of this notion 
social defeat decreases FGF-2 expression in the hippocampus (Turner et al., 
2008a) and increases vulnerability to anxiety (Kinsey et al., 2007). Furthermore, 
rats suffering low maternal care during development show low levels of 
hippocampal FGF-2 (Bredy et al., 2003) and high anxiety (Caldji et al., 1998).  
However it is unknown whether such differences in anxiety are due to differences 




Our results also demonstrate that FGF-2 increases neurogenesis by enhancing 
new cell survival selectively in LRs.  These findings are consonant with previous 
findings showing exogenous FGF-2 salvaging cell survival deficits (Rai et al., 
2007).  Interestingly, effects of FGF-2 on survival were independent of changes 
in cell proliferation.  These results parallel findings showing decrease 
hippocampal cell survival with no changes in cell proliferation after social defeat 
(Thomas et al., 2007).  They also expand on reports showing decrease FGF-2 
and low cell survival in the hippocampus of rats suffering from low maternal care 
(Bredy et al., 2003) and support our findings showing LRs with a tendency 
towards low cell survival.  Taken together our results suggest that LR’s low levels 
of hippocampal FGF-2 expression may lend high vulnerability to low cell survival 
which could in turn lead to a decrease in the generation of new neurons and new 
astrocytes.  
 
In the adult, FGF-2 shows prominent expression in astrocytes throughout the 
brain, whereas neuronal expression is almost exclusive to the hippocampus 
(Woodward et al.).  Although FGF-2 has mostly been related to neurogenesis, 
FGF-2 has also been noted to modulate the number of glial cells in the 
hippocampus (Cheng et al., 2002).  This is consistent with our findings showing 
an increase in both glial genesis and neurogenesis. However, it is worth noting 
that FGF-2 showed a larger increase in glial genesis as seen by a four-fold 
increase compared to a two-fold increase in neurogenesis. This suggests that 
FGF-2 shows a preferential increase in glial genesis. 
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 While we are not aware of FGF-2 being directly linked to hippocampal astrocyte 
differentiation, several findings have shown it modulating the expression of GFAP 
in the cortex (Reuss et al., 2003) and to synergistically participate with cilliary 
neurotrophic factor (CNTF) in promoting astrocyte differentiation (Song and 
Ghosh, 2004).  Furthermore, phenotypic analysis of BrdU+ cells support the role 
of FGF-2 in astrocyte differentiation as HR animals show an overall higher 
pattern of glial differentiation relative to LRs.  Interestingly, observed differences 
in astrocyte differentiation between control HR and LR were lost after FGF-2 
treatment.  This suggests that FGF-2 modulates the differentiation of new cells 
generated in the hippocampus translating into an enhancement of astrocytes.  
 
In conclusion our results suggest that FGF-2 plays a role in modulating anxiety 
behavior by increasing the rate of cell survival and in turn promoting the 
generation of new astocytes and neurons.  This is supported by our data showing 
LR animals, which display increased anxiety behavior as having lower basal 
levels of FGF-2 relative to the less anxious HR.  However, when LR’s 
endogenous levels of FGF-2 are increased either by EC or by exogenous 
treatment they respond with less anxiety lending their behavior become similar to 
that of an HR animal.  Moreover, FGF-2 anxiolytic effects were accompanied by 
increased new cell survival that in turn promoted the preferential increase in new 
astrocytes.  This again made the LR’s resemble that of an HR phenotype as HR 
show a higher number of newly generated astrocytes. Thus the results above 
suggest that low levels of hippocampal FGF-2 expression in LRs contribute to 
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low survival rates of newly generated astrocytes, making them more prone to 
high anxiety behavior.  Taken together the present study supports the role of 
FGF-2 as a novel mediator of anxiety-like behavior and a potential novel 











A) LR animals show decreased FGF-2 expression in the Dentae Gyrus [t(16)=2.58, p<0.05]  and 
CA3 regions of the hippocampus [t(16)=2.12, p<0.05] (n=9-10 per group). B) Representative 
images from HR and LR animals showing basal FGF-2 expression in the hippocampus. C) 
Correlation of FGF-2 expression in the hippocampal CA2 region and time spent in the open arm 
[R^2=0.53, (p<0.01] (n=11). 
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A) Overall HR animals displayed lower anxiety behavior compared to LR animals as measured by 
their increase in the percent time spent in the Illuminated Compartment [F(1,35)=7.7, p<0.01]. 
There was also a significant main effect of EC on decreasing anxiety-like behavior as shown by 
an increase in the percent time spent in the Illuminated Compartment [F(1,35)=6.02, p<.05]. There 
was also an interaction on the time spent in the illuminated Compartment [F(1,35)=6.8, p<0.05]. 
Post-hoc tests revealed a differential effect on LR EC trained versus LR control animals (p<0.01) 
(n=13-15 per group).  B) There was also a main effect of phenotype in the EPM as HR animals 
showed an higher percent of open arm entries [F(1,52)=8.1, p<0.01].  Main effects of EC in the 
EPM also show an overall increase in the percentage of open arm entries [F(1,52)=20.0, p<0.0001].   
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Figure 4-3: Environmental Complexity differentially increases Hippocampal FGF-2 
expression in LRs. 
 










A) EC results in an overall significant increase in FGF-2 expression in the dentate gyrus, 
[F(1,19)=23.3, p<0.001], and CA3 region, [F(1,19)=16.7, p<0.0001]. There was also an interaction 
effect of EC housing and phenotypic group on FGF-2 expression in the dentate gyrus, 
[F(1,19)=6.17, p<0.05] and CA3 region [F(1,19)=6.4, p<0.05]. Post-hoc revealed a differential effect 
on LR EC animals as compared to LR controls within dentate gyrus (p<0.0001) and CA3 region 
(p<0.001). (B) Representative images of FGF-2 expression in the hippocampus of HR and LR 










A) Overall main anxiolytic effects of phenotypes and treatment were observed in the LDB, as HR 
[F(1,46)=38.5, p<0.0001] and FGF-2 treated animals [F(1,46)=5.9, p<0.05] spent more time in the 
illuminated compartment. Interaction effects of treatment and phenotype where also observed in 
the LDB [F(1,46)=5.6, p<0.05].  Post-hoc analysis revealed FGF-2 treated LRs showing less 
anxiety relative to vehicle treated LRs (p<.01).  B) There was an interaction of FGF-2 treatment 
and phenotype group on reducing anxiety as measured by an increase in the percent of open arm 
entries in the EPM [F(1,46)=7.2, p<0.01] and posthoc analysis revealed effects in LR FGF-2 treated 
animals relative to LR vehicle controls (p<.01) (n=11-15 per group). 
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C) Interaction effects were also observed in the percent of time spent in the open arm [F(1,46)=6.1, 
p<0.05].  Analysis by post hoc revealed LR FGF-2 treated animals differentially showing an 
increase in the percent time in open arms (p<0.01) (n=11-15 per group). 
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A) Chronic FGF-2 results in an overall significant increase in new cell survival in the dentate 
gyrus as shown by an increase in the number of Brd-U labeled cells [F(1,16)=18.5, p<.001]. 
Furthermore there was an interaction of treatment and phenotype group [F(1,16)=5.2, p<.05], as LR 
FGF-2 treated animals showed an increase in cell survival relative to LR vehicle treated animals 
(p<.001) B) No significant effects were observed in cell proliferation as chronic FGF-2 failed to 
increase the number of Ki67 labeled cells [F(1,16)=1.1 p>.05], (n=5 per group). 
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A) Overall main effects showed HR animals showing higher number of BrdU+ astrocytes relative 
to LRs [F(1,16)=27.1, p<0.0001].  An interaction effect was also observed on the number of 
undifferentiated cells [F(1,16)=9.5, p<0.01] with post-hoc tests revealing that under vehicle 
conditions LRs show a higher number of undifferentiated cells (p<0.01) relative to vehicle HRs. B) 
Upon FGF-2 treatment HR animals showed a differential increase in the number of 
undifferentiated cells (p<.01) eliminating basal differences between HRs and LRs on the number 
of undifferentiated cells. Overall main effects showed FGF-2 treated animals showing an increase 
in the number of new neurons [F(1,16)=20.2, p<0.001] and astrocytes [F(1,16)=33.1, p<.0001], with 
significant interactions observed in the number of new neurons and astrocytes respectively 
[F(1,16)=9.7, p<0.01] [F(1,16)=9.6, p<0.01].  Post-hoc analysis revealed that FGF-2 treatment 
differentially increased the number of neurons (p<.0001) and new astrocytes (p<.0001) in LRs 
(n=5 per group).   
HR/FGF-2 LR/FGF-2 














C) HR animals showed a greater proportion of astrocyte differentiation [F(1,16)= 5.77, p<0.05] 
whereas LRs show an overall increase in the percent of undifferentiated BrdU labeled cells 
[F(1,16)= 7.73, p<0.05]. D) Overall FGF-2 treatment effects in the percent of undifferentiated cells 
[F(1,16)= 9.1, p<0.05] and its interaction [F(1,16)= 26.9, p<0.001] resulted in a disruption of HR/LR 
differences in astrocyte and undifferentiated cells.  Post-hoc revealed FGF-2 treatment decreased 




Table 4-1: FGF-2 differentially alters cell differentiation in HR and LR animals 
 
 
Table 4-1 shows the total number of BrdU+ neurons, astrocytes and undifferentiated cells along 
with their standard error of the mean in parenthesis.  Overall main effects showed HR animals 
showing higher number of BrdU+ astrocytes relative to LRs [F(1,16)=27.1, p<0.0001].  An 
interaction effect was also observed on the number of undifferentiated BrdU+ cells [F(1,16)=9.5, 
p<0.01] with post-hoc tests revealing that under vehicle conditions LRs show a higher number of 
undifferentiated cells (p<0.01) relative to vehicle HRs. Upon FGF-2 treatment HR animals 
showed a differential increase in the number of undifferentiated cells (p<.01) eliminating basal 
differences between HRs and LRs on the number of undifferentiated cells.  Overall main effects 
showed FGF-2 treated animals showing an increase in the number of BrdU+ neurons 
[F(1,16)=20.2, p<0.001] and astrocytes [F(1,16)=33.1, p<.0001], with significant interactions 
observed in the number of BrdU+ neurons and astrocytes respectively [F(1,16)=9.7, p<0.01] 
[F(1,16)=9.6, p<0.01].  Post-hoc analysis revealed that FGF-2 treatment differentially increased 
the number of new neurons (p<.0001) and astrocytes (p<.0001) in LRs (n=5 per group). 
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A) Representative image of a cluster of ki67 labeled cells marked with arrowheads. (Scale bar 20 
µm.) B) Representative image of BrdU labeled cells marked with arrowheads. (Scale bar 10µm).  
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A) Representative confocal images of BrdU/NeuN co-labelled cells and BrdU/ GFAP co-labeled 
cells (scale bar 10µm).  red labeling are BrdU positive cells, blue labeling are GFAP positive cells 
and green are NeuN positive cells. B) Arrowhead points to BrdU/NeuN co-labeled verified in 
xy,/xz axis axis. 
   yz 
  xz 
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Appendix 4-3: Differences in locomotor response to novelty in selectively bred HR and LR 
animals. 
   
Selectively bred HR and LR animals show reliable differences in locomotor response to novelty  








Appendix 4-4: Differences in anxiety response to EC and FGF-2 are not related to changes 








A) Selectively bred LR animals show no significant differences in general activity response to EC 
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The present dissertation encompasses a series of studies demonstrating a novel 
role for endogenous hippocampal FGF-2 as a mediator of anxiety-like behavior.  
In support of this concept, we show that an experience such as housing in a 
complex environment, construed to be neuroprotective, reduces anxiety while 
requiring hippocampal FGF receptor activation for such effects.  Moreover, FGF-
2’s role in reducing vulnerability to anxiety was further validated in animals 
showing genetic propensity to high anxiety.  Specifically, LR animals, which are 
genetically predisposed to exhibit high anxiety behavior, have low basal levels of 
hippocampal FGF-2 gene expression whereas their counterparts, the low anxiety 
HRs, show high basal levels of hippocampal FGF-2.  Importantly, upon exposure 
to EC, FGF-2 expression in the hippocampus of LRs becomes significantly 
increased as their anxiety levels become reduced.  Moreover, when the high 
anxiety LRs where treated chronically with exogenous FGF-2, their anxiety 
behavior was reduced to a level comparable to that of HRs, mirroring the impact 
of EC on these selectively bred animals.  Thus, LR’s appear to be genetically 
“FGF2 deficient” and more anxiety-prone, and treatments including direct 
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administration of exogenous FGF2 or exposure to a manipulation that induces 
endogenous FGF2 reverse the anxiety phenotype.  Taken together these results 
demonstrate for the first time that FGF-2 serves as endogenous modulator of 
anxiety behavior, and that its effects are partially determined by genetic factors 
but are readily modulatable by experience.     
 
Interestingly, FGF-2’s anxiolytic impact after chronic treatment stands in contrast 
to its anxiogenic impact upon acute treatment.  Thus, acute treatment with FGF-2 
increased anxiety-like behavior with particularly strong effects in the HR animals.  
This contradictory dilemma harks back to a profile of action often seen upon 
acute treatments with antidepressants (Bagdy et al., 2001). Initially, some 
antidepressant treatment regimens lead to acute anxiogenic effects before 
presenting their beneficial effects on depression and anxiety after two to three 
weeks of treatment (Dulawa et al., 2004).  This same the scenario occurred in 
our results whereby acute FGF-2 treatment was anxiogenic, whereas chronic 
FGF-2 treatment exhibited the anxiolytic response elicited by antidepressants 
and EC. This is consistent with other findings from our laboratory that showed 
that FGF-2 also has antidepressant effects (Turner et al., 2008b). Our results 
also suggest that FGF-2 may be acting in a neurotransmitter-like fashion, or at 
least mediating its behavioral effects by modulating neurotransmitter systems.  
Furthermore, they suggest that chronic FGF-2 may be mediating its anxiolytic 
impact by modulating structural plasticity, as has been proposed for chronic 
antidepressants such as SSRIs.  
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In support of this notion, our results show chronic FGF-2 increasing hippocampal 
cell genesis, by means of increasing cell survival and promoting the generation of 
new neurons and especially new astrocytes.  Similarly, HRs, which naturally 
show high levels of hippocampal FGF-2 gene expression show a tendency for 
high levels of hippocampal new cell survival while showing significantly more 
newly generated astrocytes. These results parallel effects seen after EC, wherein 
increases in cell proliferation and cell survival were observed. This led to the 
hypothesis that FGF-2 may be mediating the cell survival effects seen after EC.  
This hypothesis was tested and supported by the studies described in Chapter 2, 
which demonstrated that an FGF antagonist injected into the hippocampus 
disrupts the effects of EC on increasing hippocampal cell genesis.  However, 
both proliferation and cell survival were disrupted by the antagonist, which blocks 
the effects of all the FGF’s that impact on hippocampal receptors.  This indicates 
that while FGF-2 may be mediating the cell survival effects seen after EC, other 
FGF ligands may be participating in the modulation of EC’s impact on cell 
proliferation.  
 
The fact that FGF-2 increases hippocampal cell genesis and reduces anxiety 
presents an interesting scenario.  Thus, as mentioned above, chronic 
antidepressant treatment increases hippocampal FGF-2 gene expression (Mallei 
et al., 2002) and hippocampal cell genesis (Malberg et al., 2000) while reducing 
anxiety.  Similarly, EC increases neurogenesis reduces anxiety and increases 
hippocampal FGF-2 gene expression.  This suggests that the long-term 
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behavioral impact of both EC and antidepressants may rely on FGF-2, and that 
this growth factor exerts its effects on behavior, at least in part, by altering 
hippocampal cell genesis.  
 
The combination of using the HR-LR model and altering environmental 
complexity offers an excellent opportunity to assess both the genetic and the 
environmental factors critical in modulating vulnerability to mood disorders. 
Furthermore, these paradigms allowed the use of non-pharmacological strategies 
to demonstrate the role of endogenous FGF-2, and uncovering its function in 
modulating anxiety behavior. Key elements that have emerged in common with 
antidepressant mechanisms of action include alterations in expression levels of 
growth factors and enhanced cell genesis in the adult hippocampus.  Thus, a 
deficiency in growth factor function has been hypothesized to increase 
vulnerability to clinical depression, and antidepressants have been proposed to 
mediate their behavioral effects by increasing growth factor support, which in turn 
can alter neural plasticity including enhancement of neurogenesis. Indeed this 
appears to be the case for FGF-2, as its expression levels are low in the brains of 
severely depressed individuals, and this decrease is less marked in subjects who 
had received SSRI treatment (Evans et al., 2004) (Gaughran et al., 2006). The 
current results led us to hypothesize that a similar set of mechanisms may be 
mediating vulnerability to anxiety, an affective response that is closely linked to 
depression.  Consequently, the results of this dissertation led to the following 
extension of the previous human and animal studies:  Endogenous hippocampal 
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FGF-2 decreases vulnerability to anxiety. It does so, at least in part, by altering 
hippocampal neuroplasticity, increasing survival of adult stem cells and 
particularly the generation of new astrocytes, which may in turn provide better 
support for general hippocampal function.  
 
The above synopsis of the results presented in this project serves as a prelude to 
the discussion and general conclusions of this dissertation. 
 
Role of FGF-2 as Regulator of Anxiety 
 
As part of the results presented in this project I report that FGF-2 presents 
seemingly contradictory effects on anxiety-like behavior. In particular, during 
acute administration FGF-2 increases anxiety behavior, a result consistent with 
our findings showing that acute FGF receptor antagonism in the hippocampus 
reduces anxiety.  However, these acute results stand in contrast to our findings 
that chronic FGF-2 treatment leads to decreased anxiety, and this is 
accompanied by increased survival of newly born cells in the adult hippocampus.  
While I propose that both of these effects are mediated by the hippocampus, our 
results present a puzzling discrepancy that we aim to explain with two distinct 
mechanism of action: acute effects of FGF-2 which involve immediate 
neurotransmitter-like action, and chronic effects of FGF-2 which involves 
structural plasticity-related changes within the hippocampal circuitry.  
Furthermore, I will also discuss how the HR and LR trait differentially interacts 
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with the mechanisms of action of FGF-2 in modulating anxiety acutely and 
chronically.  
 
While the acute anxiogenic effects of FGF-2 may raise questions about its 
potential for long term treatment of anxiety and depression, it is worth mentioning 
that a similar response pattern is observed with antidepressant treatments.   
Thus, acute treatment with selective serotonin reuptake inhibitors (SSRIs) has 
been shown to cause acute anxiogenic effects (Bagdy et al., 2001), while it is 
well known that chronic antidepressants reduce anxiety (Dulawa et al., 2004). 
Taking the antidepressant treatment paradigm as a model, we can draw parallels 
to arrive at possible mechanistic explanations of the acute versus chronic 
behavioral responses to FGF-2.   On the other hand, alternate mechanisms 
linking FGF-2 to acute stress responses may also provide a viable mechanistic 
explanation of the acute anxiety responses.  
 
It is known that effective treatment regimens with SSRIs require chronic 
administration in order to see improvements in behavioral responses in humans. 
Thus most of the literature has focused on the neural plasticity mechanisms 
involving the effects of antidepressants on reversing behavioral responses 
reminiscent of depression such as anxiety.  One of the most studied and perhaps 
most widely accepted neural mechanism suggested to mediate antidepressant 
action is hippocampal cell genesis, as antidepressants such as SSRIs are well 
known to increase neurogenesis (Malberg et al., 2000).  Interestingly, 
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hippocampal FGF-2 expression is increased in response to chronic 
antidepressants (Mallei et al., 2002).  Furthermore, previous reports showed 
FGF-2 enhancing cell proliferation and cell survival (Wagner et al., 1999) (Rai et 
al., 2007). 
 
Thus, there is mounting evidence pointing to a possible role of FGF-2 in 
mediating the hippocampal cell genesis response seen after antidepressant 
treatment.  Our results in Chapter 3 support this idea as chronic FGF-2 increased 
hippocampal new cell survival.  Furthermore, we showed that experiences 
reducing anxiety such as EC require FGF-2 to increase cell genesis.   On the 
other hand experiences known to negatively impact anxiety, which serve as 
depression models, such as social defeat, (Kinsey et al., 2007)  have been 
shown to decrease FGF-2 expression in the hippocampus (Turner et al., 2008a).  
Furthermore, social defeat also decreases hippocampal new cell survival 
(Thomas et al., 2007).  Given that the effects of antidepressants on modulating 
anxiety take two to three weeks to be observed, it is reasonable to suggest that 
changes in hippocampal neurogenesis could in part be the underlying 
mechanism of such changes in behavior.  Furthermore, the relevance of FGF-2 
in reducing anxiety added to its positive impact on hippocampal cell genesis 
leads us to hypothesize that chronic FGF-2 modulates anxiety in part via an 




While the evidence linking FGF-2 to potential plasticity mechanisms reducing 
anxiety under chronic conditions is considerable, sparse reports also implicate 
this growth factor in modulating anxiety behavior under acute conditions.  For 
example, previous studies show an increase of hippocampal FGF-2 gene 
expression in response to anxiogenic stimuli, such as acute restraint (Fumagalli 
et al., 2005).  Moreover, corticosterone administration up-regulates FGF-2 in the 
hippocampus (Molteni et al., 2001) and stress-mediated increases in 
hippocampal FGF-2 require corticosterone responses (Frank et al., 2007). These 
reports suggest that hippocampal FGF-2 may participate in modulating acute 
stress related behavioral responses and that such acute modulation works in 
concert with modulators of anxiety behavior such as glucocorticoids (Wei et al., 
2004). 
 
FGF-2’s acute anxiogenic behavioral effects may well result from an endogenous 
neural stress response within the hippocampal circuitry.  Corticosterone provides 
an alerting and regulatory response to the organism when encountering 
threatening environmental or physiological stimuli (Wei et al., 2004). This, in turn, 
triggers an up-regulation of FGF-2 expression, as the FGF-2 gene predominantly 
responds to glucocorticoid receptor (GR) (Molteni et al., 2001). We hypothesize 
that this induction of FGF-2 by glucocorticoids may provide an endogenous 
protective and adaptive response to highly stressful stimuli. FGF-2 is known to be 
a necessary player in neurotrophic and neurogenic support after injury 
(Yoshimura et al., 2001), and it may play a similar neurotrophic and neurogenic 
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support role after stressful conditions, preparing the hippocampal circuitry for 
coping with imminent changes occurring in the organism’s external environment.  
Thus FGF-2 may provide an endogenous trophic support in response to 
stressors such as novelty or anxiogenic stimuli. Thus stress may induce FGF-2 
(this can also be the stress of an enriched environment), which could initially 
trigger an anxiogenic response.  In turn FGF-2 induces astrocytes, which contain 
more FGF-2 that can also be protective and lead to resilience against anxiety 
after long term treatment. 
 
The notion that FGF-2 may serve to protect the neural circuitry when an 
organism is confronted with an environmental threat is exemplified in FGF-2’s 
prevention of excitotoxic cell death (Mattson et al., 1995) via inactivation of 
NMDA receptors on hippocampal neurons (Boxer et al., 1999).  Interestingly, 
glucocorticoids reduce hippocampal cell proliferation via NMDA receptor 
activation (Cameron et al., 1995). On the other hand, glucocorticoids increase 
hippocampal FGF-2.  Thus the inactivation of NMDA receptors by FGF-2 could 
be seen as part of a negative feedback response regulating stress-related neural 
activity.  FGF-2’s inactivation of NMDA receptors may constitute a cellular 
protective response within the hippocampus, resulting from acute stress 
conditions.  In turn the anxiety behavioral response elicited by FGF-2 may help 
preserve the subsequent survival of new cells by limiting the exposure of the 
individual to additional threatening stimuli.  This endogenous mechanism would 
help counteract or reduce the deleterious effects of glucocorticoids and NMDA 
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activity such as the decrease in cell proliferation that results in response to 
stressors (Gould et al., 1997). 
 
While the current studies did not directly test the idea that acute stress is both 
anxiogenic and induces FGF-2, the impact of acute stress on FGF-2 expression 
has been previously demonstrated (Molteni et al., 2001). We suggest that the 
direct injection of FGF-2 into the hippocampus mimics the later stages of this 
proposed process—it generates an acute anxiety response while setting into 
motion the neuroprotective mechanisms that become evident upon repeated 
administration of the growth factor.  
 
Alternatively, the mechanism underlying the differential pattern of anxiety after 
acute and chronic FGF-2, may well be related to a neurotransmitter-like 
modulation of anxiety similar to that of serotonin.  This is particularly appealing 
given that acute injections with 5-HT1A receptor agonists directly into the 
hippocampus increase anxiety (File and Gonzalez, 1996).  Furthermore, chronic 
treatment with SSRIs antidepressants also reduces anxiety (Dulawa et al., 2004).  
This change in behavioral effects from being anxiogenic acutely to being 
anxiolytic chronically has been attributed to changes in serotonergic transmission 
activity. Initially drugs acting on somatodendritic 5HT1A autoreceptors directly 
such as agonists or indirectly such as SSRIs lead to a decrease in the release of 
serotonin at the synaptic cleft in the terminal projection areas. By contrast, 
chronic treatment with such drugs leads to a desensitization of 5HT1A 
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somatodendritic autoreceptors and subsequent disinhibition (File et al., 2000), 
lending to a sensitization of postsynaptic receptors, thereby decreasing anxiety.  
Given that FGF-2 follows a similar pattern from acutely being anxiogenic to 
chronically being anxiolytic, we reason that perhaps a mechanism of action of 
“cross-talk” between the FGF-2 and the serotonin system could be taking place.  
Furthermore, the fact that FGF-2 increases in response to chronic SSRI 
treatment supports the notion that FGF-2 may be acting in the synaptic 
restructuring of the serotonin system (Mallei et al., 2002).  Thus, acutely FGF-2 
may enhance anxiety by enhancing the response brought by decrease in post-
synaptic serotonergic release in the hippocampus.  On the other hand chronic 
treatment with FGF-2 may promote a sensitization of hippocampal postsynaptic 
5HT1A receptors, which may contribute to reduce anxiety.  This is especially 
plausible given that FGF-2 has previously been shown to be required for 
behavioral sensitization to drugs of abuse and it has been suggested that it does 
so in concert with neurotransmitters (Flores and Stewart, 2000).  These changes 
in serotonin receptor sensitization may in turn provide a venue for increasing cell 
genesis in the hippocampus seen in response to chronic antidepressants 
(Malberg et al., 2000). 
 
Differential responses to FGF-2 in HR and LR 
 
When presenting our results relating to the acute anxiogenic and chronic 
anxiolytic responses to FGF-2 we observed that these effects showed strong 
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interactions with the HR-LR phenotype.  Specifically, under acute administration, 
FGF-2 had a differential anxiogenic response in HR animals converting the low 
anxiety HR animal into a high anxiety LR-like phenotype.   On the other hand, 
when FGF-2 was injected chronically, the typically high anxiety behavior of LRs 
changed to resemble that of an HR animal.   This result was particularly intriguing 
as HR animals show higher basal levels of FGF-2 relative to the high anxiety 
LRs.  Thus, chronic FGF-2 administration appears to rescue the low levels of 
FGF-2 in the hippocampus of the LR animals, rendering them HR-like in terms of 
anxiety behavior. 
 
Thus, it appears that low levels of hippocampal FGF-2, as seen in LRs, may 
enhance vulnerability towards high anxiety-like behavior.  Conversely, high levels 
of FGF-2 in the hippocampus can decrease the vulnerability to anxiety, be it by 
genetic endowment as seen in HRs or by chronic administration as seen in the 
LRs repeatedly treated with FGF2.  Moreover, this same set of mechanisms can 
be invoked in conjunction with environmental complexity, a treatment that led to a 
differential increase in FGF-2 in LRs in addition to a differential decrease in their 
anxiety-like behavior.  This further supports the view that the high anxiety 
behavior seen in LRs could be attributed to low levels of FGF-2.   Thus, EC may 
provide an alternative approach to decreasing vulnerability to anxiety-like 
behavior by increasing hippocampal FGF-2 in animals such as LRs that are 




By contrast, the acute anxiogenic effect of FGF-2 in HR’s, along with its lack of 
anxiolytic effectiveness when administered chronically to these same animals, 
suggest that FGF2 may not be a universally effective strategy for reducing 
anxiety behavior.  In HRs the support of FGF- 2 seems to be built as part of their 
genetic endowment and inducing or delivering more FGF-2 may perhaps 
“saturate” the system. Thus, acutely, FGF2 readily elicits in HR’s the anxiety 
response discussed above, whereas chronically FGF2 appears ineffective in 
altering anxiety behavior in these animals—they appear “treatment resistant”.  It 
is therefore reasonable to suggest that an optimal level of FGF-2 is required for 
effectiveness in controlling anxiety behavior. This level is achieved under basal 
conditions by the HRs and is only reached by LR’s under enriched conditions 
such as EC.  
 
 While this may be the case under basal conditions, it is conceivable that, under 
stressful conditions, FGF-2 treatment might prove beneficial even to the HR 
animals. It should be noted that in response to strong stressors such as social 
defeat, HR’s behavior comes to resemble that of LR’s (Kabbaj et al., 2001). 
Indeed, certain stressors have a stronger impact on HRs than they do on LR’s.   
Remarkably these same manipulations decrease hippocampal FGF-2 expression 
(Kabbaj et al., 2001). Thus it is conceivable that the differential impact of stress in 
HRs might be associated with an increased requirement for FGF-2.  In other 
words, under normal circumstances HRs exhibit low vulnerability to anxiety 
behavior, in part due to high hippocampal levels of FGF-2.  However, HR animals 
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are highly reactive to their environment, and a chronic stressor may both lead to 
profound behavioral changes and deplete the stores of FGF2 in the HRs. Thus, it 
would be critical to determine whether manipulations such as social defeat have 
a particularly strong impact on FGF2 expression in the HR animals, and whether 
they would now profit from FGF2 treatment at least as much, or possibly more 
than, the LR animals.  
 
This scenario is plausible as antidepressant treatment in humans is only effective 
when clinically needed, whereas its administration in a non-depressant individual 
may not prove beneficial and may carry untoward side effects, such as increased 
anxiety.  This is important because when addressing vulnerability it is imperative 
to take contextual conditions into account as well as individual genetic 
endowment.  Thus, the FGF-2 treatment strategy for anxiety may be beneficial to 
LRs under normal circumstances whereas in HRs the treatment may be effective 
only under stressful conditions.  One particular piece of evidence to support such 
an idea is that while HR and LR differ on basal levels of anxiety under normal 
conditions, when exposed to stronger stressors the typical behavioral responses 
seen in HRs become more LR-like (Kabbaj et al., 2001). It is possible that under 
such circumstances we might see FGF-2 having an anxiolytic response in HRs 
and perhaps that a chronic treatment might be a viable alternative.  
 
Finally, it is worth mentioning that under normal conditions laboratory animals 
such as HRs and LRs live in environments of reduced complexity and have 
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severe limitations of physical activity compared to their wild counterparts.  The 
above studies showing increased neurogenesis and reduced anxiety following 
FGF-2 and EC could therefore be viewed as a decrease in neurogenesis and an 
increase in anxiety following environmental deprivation (Gould et al., 2000).  
Similarly, it could be viewed that HRs are less affected by environmental 
deprivation as opposed to LRs, and exposure to EC rescues the stressful impact 
of living in such deprived conditions.  Thus the apparent genetic differences 
between HRs and LRs may not necessarily account for the basal differences in 
FGF-2 expression, but in response to the environmental deprivation.  It could be 
that environmental deprivation has a bigger toll on LRs, that translates to a 
decrease in FGF-2 expression in the hippocampus, which in turn results in an 
increase in anxiety. Furthermore it could be that such effects of environmental 
deprivation were normalized by FGF-2 and EC in LRs whereas no correction was 
necessary in HRs as they might be more resilient to the negative impact of 
environmental deprivation.  
 
 In conclusion, FGF-2 has different effects in HRs and LRs on anxiety behavior.  
Although the selectively bred HR and LR animals provide an excellent model of 
genetic vulnerability to anxiety, it is also appealing to have these animals as a 
potential pharmacogenomics model.  This is viable to the extent seen in our 
results with FGF-2 as well as in previous studies where HR and LR animals 
showed a differential response profile to antidepressants (Jama et al., 2008). It is 
also critical to assess their responsiveness under appropriate contextual 
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conditions, for example examining treatment responses under basal versus 
stressful conditions. Such an approach would provide a more complete 
characterization of the differential treatment responsiveness of HR and LR 
animals.  
 
The hippocampus as a mediator of anxiety-like behavior 
 
Our results suggest a novel role for the FGF system in the modulation of anxiety-
like behavior that may be mediated by the hippocampus.  The hippocampus has 
mostly been studied for its role in learning and memory (Scoville and Milner, 
2000), and we recognize that the hippocampus has not particularly been 
considered as a key region responsible for modulating anxiety-like behavior.  
However, recent evidence suggests that the hippocampus may play a functional 
role in modulating anxiety-like behavior.  For example, hippocampal lesions and 
direct intra-hippocampal pharmacological treatments have been shown to alter 
anxiety-like behavior (Bannerman et al., 2004, Engin and Treit, 2008).  In the 
following section, we will focus our attention on the role of the hippocampus in 
modulating anxiety-like behavior.   
 
The fact that hippocampal FGF-2 modulates anxiety-like behavior was initially 
supported by our findings that showed HR-LR basal differences in FGF-2 
expression in the hippocampus. HRs, which typically exhibit low levels of anxiety-
like behavior, displayed higher expression of FGF-2 in the hippocampus than 
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LRs.  Moreover, hippocampal FGF-2 increased in response to EC, which we 
showed to be anxiolytic, supporting the supposition that high expression of 
endogenous FGF-2 in the hippocampus results in a phenotype with decreased 
anxiety-like behavior.  Finally, FGF-2 itself reduced anxiety-like behavior further 
validating its ability to modulate anxiety-like behavior.  However, these results 
were correlational, as FGF-2 was not shown to directly act on the hippocampus.   
 
Nonetheless, one particular set of results, which unequivocally implicated the 
hippocampus in anxiety-like behavior, was the effects of direct microinjections of 
an FGF receptor antagonist.  In this set of studies, we saw that intra-hippocampal 
microinjections with an FGF receptor antagonist significantly reduced anxiety-like 
behavior.  These results are in agreement with the anxiogenic effects observed 
following systemic FGF-2 injections and suggest that the hippocampus may play 
a functional role in regulating anxiety-like behavior.  Furthermore, the 
microinjection study also pointed to the specific importance of the hippocampus 
in modulating individual differences in anxiety-like behavior. Here, we saw that 
the acute anxiogenic effects of FGF-2 were more prominent in HRs, whereas the 
chronic anxiolytic effects of FGF-2 were observed in LRs. 
 
The role of the hippocampus in modulating individual differences in anxiety-like 
behavior has previously been shown in the HR an LR model (Kabbaj et al., 
2000).  Specifically, HR and LR animals have been shown to exhibit differences 
in hippocampal glucocorticoid receptor (GR) expression. In this example, LRs 
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displayed higher expression of GR relative to HRs.  These differences in 
hippocampal GR expression are, in part, responsible for the HR-LR differences in 
anxiety as hippocampal microinjections with a GR antagonist have been shown 
to disrupt individual differences.  Furthermore, several models known to show 
individual differences in anxiety-like behavior have yielded results reminiscent of 
hippocampal differences found between HR and LR animals.  For example, 
offspring of dams that exhibited decreased maternal behavior show increased 
anxiety-like behavior relative to offspring of mothers that exhibited greater 
maternal attention (Caldji et al., 1998).  Although these differences are not 
necessarily dependent on differences in the hippocampus, there is evidence that 
adult offspring of mothers that exhibited differences in maternal behavior display 
differences in hippocampal gene expression and morphology similar to those 
observed between HR and LR animals. To this end, animals with reduced 
anxiety-like behavior and greater maternal behavior showed higher levels of 
FGF-2 and higher rates of cell survival in the hippocampus (Bredy et al., 2003).   
Taken together, the results presented in this dissertation along with a few 
previous studies suggest that the hippocampus is a strong modulator of 
individual differences in anxiety-like behavior. 
 
Although the functional relevance of the hippocampus in anxiety-like behavior is 
still controversial, several reports support this function in addition to its primary 
role in learning and memory.  Previously, lesion studies have shown the 
hippocampus to be involved in anxiety-like behavior. For example, hippocampal 
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lesions resulted in decreased anxiety-like behavior (Bannerman et al., 2002).   
Interestingly, evidence supports an anatomical segregation within the 
hippocampus, whereby the ventral hippocampus is predominantly involved in 
anxiety modulation and the dorsal hippocampus is predominantly involved in 
learning (Bannerman et al., 2004).   
 
Studies have demonstrated that ventral lesions decrease anxiety-like behavior 
with no effects observed in the dorsal hippocampus (Bannerman et al., 2003). 
Specifically, anxiolytic effects of lesions to the ventral hippocampus have been 
demonstrated in a series of tests of anxiety-like behavior including the novelty-
suppressed feeding test, the light-dark box test, the social interaction test and the 
elevated-plus maze.  On the other hand, when the dorsal hippocampus was 
lesioned, deficits were observed in spatial learning and memory without any 
observable effects on anxiety-like behavior.  Interestingly, ventral hippocampal 
lesions did not affect spatial learning.  Accordingly, several authors have 
attributed a double dissociation of the effects of ventral and dorsal hippocampal 
lesions, where the dorsal hippocampus participates on spatial learning and 
working memory tasks and the ventral hippocampus has a preferential role in 
anxiety-like behavior (Bannerman et al., 2004).   
 
Although the reports mentioned above support the notion that the ventral 
hippocampus is involved in the modulation of anxiety, it is important to mention 
that such conclusions go beyond anxiety, and extend their findings to fear 
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learning.  As several of the above-mentioned results suggest that the ventral 
hippocampus modulates anxiety-like behavior, further results also suggest that 
ventral hippocampal lesions reduce freezing behavior after cued and contextual 
fear conditioning (McHugh et al., 2004).  Thus, it is important to make a 
distinction between fear conditioning and anxiety-like behavior and acknowledge 
that studies often include fear conditioning as a measure of anxiety even though 
fear conditioning has a learning component. In this dissertation, none of the 
measures of anxiety used involved learning, as the anxiety tests were chosen to 
be representative of spontaneous anxiety.  Furthermore, previous findings that 
ventral hippocampal lesions altered freezing on cued and contextual fear 
conditioning supports the notion that an interaction with the amygdala is crucial 
for modulation of fear and anxiety.  Thus, the ventral hippocampal modulation of 
both anxiety and fear has an intricate circuitry associated with the amygdala, 
especially given that connections between the hippocampus and amygdala are 
via the ventral hippocampus (Ishikawa and Nakamura, 2006).  This is particularly 
important as lesions within the ventral hippocampal subregion may well be 
affecting input and outuput connections that can actively participate in complex 
interactions between the amygdala and cortical regions (Ishikawa and 
Nakamura, 2003). 
 
 Although fear and anxiety seemingly go hand in hand, it is important to 
distinguish between the two in order to determine the role of the ventral 
hippocampus in anxiety-like behavior, as the distinction is of utmost importance 
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to review in this dissertation.  “Fear refers to a phasic response to explicit 
conditioned aversive cues whereas anxiety is a more tonic response to diffuse 
unconditioned aversive cues or situation” (Bannerman et al., 2004).  Although the 
above-mentioned reports suggest a favored role for the ventral hippocampus in 
anxiety-like behavior, it is more appropriate to state that the ventral hippocampus 
participates in the modulation or inhibition of fear associated responses that may 
also be behaviorally present on measures of anxiety.  Such assumptions are 
supported by studies which suggest a role for the hippocampus in “behavioral 
inhibition” as defined by an adaptive process whereby an organism suppresses 
behaviors that are not appropriate when confronted with mildly stressful stimuli 
(Bannerman et al., 2004). 
 
The evidence above citing the ventral hippocampus as a key component of the 
hippocampal modulation of anxiety-like behavior appears to be in conflict with the 
results presented in this dissertation given that administration of an FGF 
antagonist into the dorsal hippocampus reduced anxiety-like behavior in both the 
elevated-plus maze and open field test.  However, it is worth noting that we did 
not verify whether injections into the ventral hippocampus would have similar or 
more pronounced anxiolytic effects. Nonetheless, the majority of the literature 
supports the preferential role of the dorsal hippocampus in spatial learning and 
memory (Bannerman et al., 2003). However, there is substantial evidence 
supporting the role of the dorsal hippocampus in various measures of anxiety-like 
behavior. The role of the dorsal hippocampus in mediating anxiety-like behavior, 
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is supported by studies showing direct microinjections having profound effects on 
both increasing and reducing anxiety-like behavior that varies by 
neurotransmitter system (Engin and Treit, 2008).  One such recent finding 
reported that direct microinjection of substance P into the dorsal but not the 
ventral hippocampus had anxiolytic effects on the several anxiety tests (Carvalho 
et al., 2008). Moreover, dorsal hippocampal activation of the GABAregic system 
with several agonists resulted in anxiolytic effects (Rezayat et al., 2005). While 
benzodiazepine antagonists are able to block the anxiolytic effects of GABA-A 
agonists, no effects were observed when the compounds were microinjected 
alone. This suggests that although GABA modulates anxiety in the dorsal 
hippocampus, GABA-A receptors do not maintain a tonic modulation of anxiety-
like behavior in the dorsal hippocampus.  Similarly, as presented earlier in this 
chapter, other neurotransmitters systems, such as the serotonergic and 
cholinergic systems, have been shown to actively play a role in the modulation of 
the impact of the dorsal hippocampus on anxiety-like behavior.  Specifically, 
dorsal intra-hippocampal microinjections with 5-HT1A agonists, such 8-OH-
DPAT, showed an anxiolytic effect.  Moreover, indirect acetylcholine agonists, 
such as the acetylcholinesterase inhibitor physostigmine, also showed anxiolytic 
effects following microinjection into the dorsal hippocampus (Engin and Treit, 
2007).  
 
Although we attribute endogenous FGF-2 mRNA differences in the hippocampus 
to differences in anxiety it is important to note that other anatomical regions may 
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also be participating in such behavior.  Moreover, it is possible that the effect of 
the FGF-2 protein may extend to other input and output regions connecting to the 
hippocampus.   
 
As mentioned earlier, FGF-2 is widely expressed in the rat brain including other 
regions associated with anxiety-like behavior such as amygdala, locus coeriliues, 
dorsal raphe and medial prefrontal cortex.   Anatomical mapping of FGF-2 has 
shown that FGF-2 synthesizing cells show colocalization with FGF-2 protein 
expression in areas such as the hippocampus (Gonzalez et al. 1995).  However, 
it has been shown that FGF-2 mRNA shows low abundance in the dentate gyrus, 
whereas protein expression is very high in abundance.  Importantly, though the 
expression of FGF-2 and FGFr1 in the hippocampus is much higher in the CA2 
and CA3 respectively.  Thus given that FGF-2 is a diffuseable protein it is 
possible that FGF-2 could also be acting outside the dentate gyrus.  This is 
highly probable given that FGF receptors are mostly expressed within axonal 
fibers and that the dentate gyrus itself show low protein expression of FGF 
receptors.  Thus it is plausible that FGF-2 synthesize in the dentate gyrus could 
be acting in other sub-regions of the hippocampus or other anatomical locations 
within the brain.   This is particularly possible for regions in which FGF-2 
synthesizing cells are found in low abundance such as the amygdala and dorsal 
raphe.  Thus such regions may require the synthesis of FGF-2 stemming from 
the hippocampus.  However, in support of our effects of chronic FGF-2 on 
neurogenesis and anxiety FGFr1 mRNA is highly expressed in the dentate gyrus.  
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Although these findings do not parallel the low protein expression of this receptor 
it is well known that FGFr1 is required for hippocampal neurogenesis (Ohkubo et 
al 2004). 
 
Taken together, these reports further support the role of the hippocampus as a 
key modulator of anxiety-like behavior and expand on the possibility that FGF-2 
may be acting in concert with several transmitters systems within the 
hippocampal circuitry to modulate anxiety-like behavior. Furthermore, the 
hippocampus may be the site whereby chronic FGF-2 can modulate anxiety-like 
behavior.  Finally, the anxiolytic effect of FGF-2 may be related to the effect of 
FGF-2 on cell genesis.  Differences in cell genesis following FGF-2 favor an 
increase in cell survival followed by a preferential increase in glial cell 
differentiation. 
 
Differential impact of FGF-2 on hippocampal cell genesis 
 
Chronic FGF-2 increased new cell survival selectively in LRs.  These findings are 
consistent with previous findings that showed exogenous FGF-2 rescued deficits 
in cell survival in middle aged animals (Rai et al., 2007).   The fact that LRs 
showed lower cell survival than HRs is also consistent with reports of decreased 
FGF-2 and decreased cell survival in the adult hippocampus of offspring of 
mothers with reduced maternal behavior (Bredy et al., 2003).  Taken together, 
LR’s low expression of hippocampal FGF-2 may be associated with lower cell 
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survival which could, in turn, lead to decreased cell genesis, particularly in the 
production of astrocytes.  
 
The impact of FGF-2 on cell genesis has mostly been associated with 
neurogenesis; however, our results showed that chronic FGF-2 could 
preferentially modulate the number of glial cells in the hippocampus.  Following 
FGF-2 treatment, there was a four-fold increase in the production of new 
astrocytes compared to a two-fold increase in neurogenesis.  These results are 
consistent with FGF-2 knockout animals exhibiting a reduction in both glial 
genesis and neurogenesis (Cheng et al., 2002). Although there were a 
significantly lower number of BrdU labeled astrocytes in LRs, FGF2 promoted the 
differentiation of both neurons and astrocytes and preferentially increased glial 
genesis in LRs. Thus, FGF-2 preferentially promoted glial differentiation in LRs.   
 
Phenotypic analysis of BrdU+ cells in vehicle-treated animals supports the role of 
FGF-2 in astrocyte differentiation, as HR animals showed an overall higher 
pattern of glial differentiation of BrdU+ cells relative to LRs. Interestingly, HR and 
LR control animals exhibited differences in astrocyte differentiation. However, 
treatment with FGF-2 ameliorated these baseline differences in astrocyte 
differentiation.  To our knowledge, FGF-2 has not previously been directly linked 
to astrocyte differentiation; however, several findings have shown FGF-2 to 
modulate the expression of GFAP in the cortex (Reuss et al., 2003) and to 
synergistically participate with CNTF in promoting astrocyte differentiation (Song 
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and Ghosh, 2004). This suggests that FGF-2 may modulate differentiation of 
newly-generated cells in the hippocampus, and this modulation may translate 
into an enhancement of GFAP-expressing astrocytes. 
 
Several reasons could explain why FGF-2 showed a preference to promote the 
differentiation of GFAP-positive BrdU cells.  As mentioned above, FGF-2 may 
participate in a regulatory mechanism that supports the promotion of glial fate 
determination.  Additionally, FGF-2 may also be promoting an increase in the 
GFAP-expressing primary Type B progenitor cell pool (Zheng et al., 2004) 
(Doetsch, 2003) 
 
The subgranular zone of the dentate gyrus contains two types of dividing cells 
that give rise to new neurons.  The slowly dividing Type B cells that express the 
intermediate filament GFAP, and the Type D precursor cells that express 
markers of differentiating neurons (Doetsch, 2003).  The duration of our 
experimental design enabled us to see the terminal differentiation of BrdU 
labeled cells. Here, neuronal differentiation was corroborated with NeuN co-
labeling, and an increase in the astrocyte differentiation was verified with GFAP 
co-labeling.  However, the apparent increase in astrocyte differentiation may 
actually reflect an increase in the GFAP expressing Type B cell pool and not 
necessarily the number of astrocytes. The majority of cells generated in the 




The GFAP-expressing progenitors reside within the subgranular zone and can be 
further categorized into two subtypes as follows: radial glial-like cells and 
horizontal cells.  Radial cells extend prominent processes along the granule cell 
layer as well smaller processes at the base of the subgranular zone.  The 
horizontal cells lie at the base of the subgranular zone and lack radial processes 
(Ma et al., 2005).  The radial GFAP astrocytes are sometimes referred also as 
the Type 1 progenitors and act as the primary slowly dividing progenitors that 
give rise to the Type D progeny which ultimately become new neurons (Doetsch, 
2003). These radial GFAP astrocytes cells interact extensively with clusters of 
type D cells which snuggle themselves within the radial processes and migrate 
their way into the granule cell layer.  Based on our data, it is plausible that 
chronic FGF-2 may have enhanced the ability of the Type B GFAP-expressing 
cells to self-renew and thereby increased the stem cell pool in LR animals 
(Doetsch et al., 2002).  
 
The pattern of division of Type B cells in vivo is unknown; hence, it is not clear 
whether type B cells divide symmetrically, asymmetrically or both.  However, 
factors such as FGF-2 and epidermal growth factor (EGF) are thought to be 
essential constituents of the stem cell niche where GFAP-expressing Type B 
cells are thought to maintain the structural milieu. Interestingly, FGF-2 and FGF 
receptors are thought to be required for proliferation of Type B cells (Zheng et al., 
2004). As mentioned above, growth factors are known to have positive effects on 
cell proliferation and self-renewal, as well as significantly impact cell fate 
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determination (Palmer et al., 1999). Thus, FGF-2 could act by promoting the self-
renewal of Type B cells along with promoting cell survival.  This, in turn, would 
lead to an increase in GFAP-labeled dividing cells as seen in LRs.   
 
Although the above scenario presents an alternative explanation to the 
preferential increase in the number of GFAP-positive cells, some cells could have 
become typical or horizontal astrocytes, whereas other cells could have become 
Type B cells.  Thus, an increase in GFAP-expressing BrdU cells could be merely 
one of the responses observed after FGF-2 treatment.  
 
There is scarce evidence to suggest that FGF-2 has an impact on type B cells in 
the hippocampus. More than likely, multiple cells responded to FGF-2.  Although 
this has not yet been shown in vivo with FGF-2, there is evidence that another 
growth factor, EGF, has distinct effects on proliferation and differentiation on 
Type B and Type C cells in the subventricular zone.   
 
The subventricular zone stem cell categorization presents some similarities to the 
dentate gyrus neural stem cells.  In the subventricular zone (SVZ), Type B cells 
are GFAP-expressing slowly dividing cells, whereas as the Type C cells are 
transit amplifying cells similar to the type D cells in the hippocampus. The Type D 
cells ultimately become type A neuroblasts.  EGF resulted in an increase in type 
C cell self-renewal due to an increase in proliferation and a stop in neuroblast 
production (Doetsch et al., 2002).   Thus, EGF both increased proliferation and 
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had a negative effect on the production of new neurons.  Although this was not 
the case in our results because the increase in GFAP cells was not at the 
expense of new neurons, it presents a scenario where specific cell types respond 
to growth factors in characteristic ways to regulate differentiation.   
 
In a different example with a growth factor similar to FGF-2, platelet-derived 
growth factor (PDGF) had a direct impact on Type B cells of the SVZ.  
Specifically, type B cells express the PDGF receptor and respond with increased 
proliferation upon ligand binding and result in a differentiation pool composed 
mostly of oligodendrocytes (Hart et al., 1989).  This is interesting because, as 
mentioned previously, the Type B neural stem cells give rise to Type C or Type D 
cells and the result is usually the generation of new neurons.  Thus, growth 
factors seem to play a regulatory role in neural stem cell differentiation in a 
manner that is cell-type specific, as well as growth factor specific whereby certain 
stimuli may promote glial or neuronal differentiation or neither. Finally, growth 
factors may regulate the balance of new neurons generated by promoting the 
differentiation of glial cells, by promoting self-renewal or by stopping the 
differentiation of neuroblasts. 
 
The multi-faceted ability of growth factors is particularly applicable given that HR 
animals responded with an increase in non-differentiated cells.  In HRs, FGF-2 
provided the stem cell niche with an excess of FGF-2, which ultimately led to an 
arrest in the differentiation of new neurons without affecting the survival of new 
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cells.  That is, FGF-2 perhaps may have provided the ingredients necessary for 
new cell survival.  FGF-2 may also have activated Type B cells or other 
molecules within the niche to respond in manner that was not conducive to the 
generation of new neurons similar to the above-mentioned example with EGF in 
the SVZ.   
 
Another remaining question is how LR animals may have benefited from an 
increase in new GFAP-expressing cells and a decrease in the number of 
undifferentiated cells. Perhaps FGF-2 activated a quiescent stem cell niche in 
LRs that resulted from low levels of FGF-2.  The prolonged low levels of FGF-2 in 
the subgranular zone may have inhibited the self-renewal or proliferation of Type 
B cells, which in turn, may have prevented the generation of new cells.  It is 
plausible that, upon treatment with FGF-2, the niche may have responded in a 
such that new GFAP Type B cells were recruited in order to promote the 
generation of new neurons (Song et al., 2002).   
 
An alternative scenario could also help explain how the deficit in GFAP-
expressing BrdU labeled cells was rescued upon FGF-2 treatment in LRs.  
During the aging process, the overall levels of FGF-2 in the dentate gyrus 
decrease dramatically.  Furthermore, a decrease in the rate of cell survival in the 
dentate gyrus has also been reported (Shetty et al., 2005).  Moreover, aging rats 
suffer from delayed neuronal differentiation of newly generated cells in the 
dentate gyrus (Rao et al., 2005).  This delayed differentiation of neurogenesis 
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has been attributed to the decrease in the levels of FGF-2 in the dentate gyrus.  
Interestingly, the deficits in the levels of FGF-2 in the dentate gyrus have been 
explained by a decrease in the number of FGF-2 synthesizing astrocytes (Shetty 
et al., 2005).  Thus, it is plausible that a similar phenomenon may be occurring in 
the dentate gyrus of LRs, where we have observed low levels of FGF-2.  The 
decrease in FGF-2 observed in LRs could be negatively impacting the 
differentiation of newly generated cells by slowing the progress of differentiation 
thus leading to a higher number of undifferentiated cells under basal conditions.  
Consequently, treatment with FGF-2 may have restored the deficits in cell 
survival and the progress of differentiation leading to more neurons and 
astrocytes. 
 
This reestablishment of an active stem cell niche coupled with the recruitment of 
Type B cells via treatment with FGF-2 could help explain the increase in new cell 
genesis in LR animals.  I hypothesize that such restoration could lead to an 
increase in neurons and astrocytes within the hippocampal dentate gyrus. This 
increase in new hippocampal cells could potentially contribute to a decrease in 
anxiety-like behavior in LR animals. 
 
These ideas present an interesting question of whether FGF-2 itself is prompting 
neurogenesis or whether an increase in astrocyte cells synthesizing FGF-2 are 
doing so.  Our hypothesis is that it is a combination of both so that; FGF-2 
induces astrocytes, and in turn astrocytes synthesize FGF-2 in a self-amplifying 
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the process.  The chronic treatment with FGF-2 provided an increase in the 
survival of FGF-2 synthesizing astrocytes, which in turn provide the support for 
Type B cells to divide and promote the survival of new neurons.  Thus the effects 
of chronic FGF-2 are two-fold one direct and one indirect.  The direct impact of 
chronic FGF-2 is to promote the survival of astrocytes cells synthesizing FGF-2.  
Upon increase availability of such astrocytes newly dividing cells are recruited 
and promoted to differentiate into neurons by the FGF-2 that has been 
synthesized from the newly survived astrocytes.  Such mechanisms provides a 





FGF-2 expression was previously shown to be decreased in the brain of severely 
depressed individuals (Evans et al., 2004, Gaughran et al., 2006). However, it 
remained unclear whether this was a consequence of the illness or whether FGF-
2 plays a primary role in the control of mood and emotions. I, therefore, 
undertook a series of studies using animal models to ask whether members of 
the FGF family can indeed modulate   emotionality, and whether they may 
constitute predisposing factors for individual differences in emotional reactivity.  
In this dissertation I focused on the role of the FGF-2 in anxiety-like behavior, 
given that there is significant co-morbidity between anxiety and major depression 
and that there is mounting evidence that the two disorders may be closely 
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associated due to a common etiology or risk factors (Gorwood, 2004).  In order to 
test the role of FGF-2 in anxiety, I relied on two animal models; one which relied 
on genetic selection strategy in Sprague-Dawley rats to enhance basal 
differences in anxiety-like behavior (Stead et al., 2006) and another which made 
environmental conditions more complex.   These models enabled us to test both 
the possible genetic role of FGF-2 and its implication as a result of environmental 
modulation.  Furthermore, we administered FGF-2 in order to directly test its role 
in modulating anxiety-like behavior and its impact on hippocampal cell genesis. 
 
The discussion above recapitulates the findings supporting the novel role of 
hippocampal FGF-2 in mediating anxiety-like behavior and hippocampal cell 
genesis.  We have found that endogenous FGF-2 reduced vulnerability to 
anxiety-like behavior by genetic propensity, as seen in HRs, and by impact of 
experience, as seen in LRs following EC. In summation, EC selectively increased 
FGF-2 and reduced anxiety-like behavior in LRs. More importantly, we saw that 
treatment with FGF-2 differentially reduced anxiety in LRs.  Furthermore, the 
functional role of hippocampal FGF-2 in experience-dependent anxiety-like 
behavior was supported by the fact that an FGF receptor antagonist blocked the 
anxiolytic effect of EC. Taken together, our results present FGF-2 as a novel 
mediator of individual differences and experience-dependent anxiety-like 




Moreover, we expanded on the role of hippocampal FGF-2 on mediating anxiety-
like behavior by showing the selective impact of FGF-2 on hippocampal cell 
genesis in LR animals.  First, we showed that exposure to EC resulted in higher 
rates of cell proliferation and cell survival in the hippocampus.  Moreover, FGF-2 
facilitated a selective enhancement in cell survival in LR animals.  Thus, chronic 
treatment with FGF-2 for a period of three weeks increased cell survival in the 
hippocampus of LRs.  These results followed a similar pattern seen in response 
to three weeks of EC where we observed increased FGF-2 expression in LRs.  
The increase in new cell survival following FGF-2 resulted in a preferential 
increase in newly generated astrocytes in the hippocampus.   Therefore, FGF-2 
may reduce anxiety-like behavior by increasing the production of new astrocytes 
in the hippocampus.   
 
In support of this dissertation, recent results from our group support the 
importance of the FGF system in depression research, as FGF-2 has been 
demonstrated to act as an antidepressant in the Porsolt Swim Test (Turner et al., 
2008b).  Furthermore, antidepressant drugs have been shown to increase FGF-2 
expression (Mallei et al., 2002) and to enhance neurogenesis (Malberg et al., 
2000). Our body of work is consistent with the current hypothesis that a 
deficiency in growth factors represents a vulnerability factor for mood disorders 
(Duman and Monteggia, 2006) and that the induction of growth factors is critical 




Surprisingly, this dissertation also suggests that EC may mimic the effects of 
FGF-2 and that its behavioral effects may resemble that of antidepressants. EC 
functioned to rescue LRs low expression of hippocampal FGF-2, and the result 
was an increase in hippocampal cell genesis and a subsequent reduction in 
vulnerability to anxiety. These results also support the hypothesis that low 
expression of FGF-2, as a result of genetic propensity and/or environmental 
influence, may contribute to the vulnerability of a depression-like phenotype, as 
increased anxiety is often observed in major depressive disorder (MDD).   
 
In summary, decreased levels of FGF-2 may be involved in the pathophysiology 
of mood disorders, and antidepressants or EC may exert their effects on 
hippocampal cell genesis by increasing FGF-2.   More importantly, our findings 
suggest that FGF-2 is not only a mediator of mood disorder pathology but may 
also influence the vulnerability to anxiety-like behavior in the context of genetic 





In my discussion above I suggest that hippocampal FGF-2 reduces vulnerability 
to anxiety via an enhancement of cell genesis in the hippocampus.  While I 
provide evidence to support such a hypothesis it is apparent that most if these 
data is correlational and a direct role of hippocampal cell genesis on behavior is 
not directly provided.  As a result future studies should be aimed at exploring the 
direct role of hippocampal cell genesis on anxiety behavior.  To this end potential 
studies should tackle directly the blockade of ongoing hippocampal cell genesis.  
By blocking ongoing hippocampal cell genesis either with viral vectors at aimed 
killing dividing cells or chemical agents we could then test the effects of such 
treatment on anxiety behavior.  Such studies could potentially show whether 
neurogenesis is required for decrease anxiety-like behavior.  
     
Based on the evidence presented above and our conclusions, future translational 
studies should also be aimed at testing the potential therapeutic value of models 
reminiscent of EC on individual differences in anxiety.  One interesting study 
could potentially identify individual differences in anxiety behavior using 
behavioral measures such as those used during clinical trials.  One example 
would be to characterize individual differences in anxiety with questionnaires or 
similar measures.  Once individuals with high anxiety are differentiated from 
those with low anxiety, a potential next step could be to the test the impact of 
models similar to EC on their anxiety behavior.  More importantly if such studies 
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do show some promise it would be interesting to follow them with genetic testing 
to identify potential genetic markers predictive of such treatment response. 
These would include the potential identification of single nucleotide 
polymorphims (snps) on the FGF-2 gene to see if they predict differences in high 
versus low anxiety or treatment response.  One other translational study could 
also test the impact of FGF-2 on anxiety behavior in high anxiety human 
individuals.   
 
In conclusion future studies should be aimed at testing the potential therapeutic 
value of EC models in human anxiety patients.  These studies could potentially 
provide a novel treatment strategy for treatment resistant populations suffering 
form anxiety disorders.  
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Appendix 5-1: Schematic model: FGF-2 reduces anxiety-like behavior   
 
 
Schematic model of my hypothesis: Hippocampal FGF-2 reduces anxiety behavior by 
promoting glialgenesis and neurogenesis in the hippocampus. Low levels of hippocampal 
FGF-2 brought by genetic endowment contribute to a vulnerable phenotype as seen in LRs. 
Increasing hippocampal levels of FGF-2 by exogenous treatment or environmental complexity 
increases the survival of adult born cells which in turn lead to an increase in the generation of 
new astrocytes and new neurons.  This net increase in astrocytes and neurons provide an overall 
support to the hippocampal circuitry helping reduce anxiety.  
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Appendix 5-2: Representative images of TypeB GFAP expressing cells 
 
 
Arrowhead marks a GFAP expressing cell (blue) wrapping around BrdU/NeuN (red/green 
respectively) positive cell, resembling Type B cells.  Arrow marks a GFAP expressing cell (blue) 








Cell types found in the subgranular zone of the dentate gyrus as part of the stem cell niche. 
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